Understanding the BED capture enzyme immunoassay (CEIA): measuring HIV-1 incidence in cross-sectional studies by Marinda, Edmore
Title: Understanding the BED Capture Enzyme 
Immunoassay (CEIA): Measuring HIV-1 incidence 
in cross-sectional studies 
 
 
Edmore Marinda  
Student number - 12840 
 
 
 
A thesis submitted to the Faculty of Medicine, University of the Witwatersrand, in 
fulfilment of the requirements for the degree of Doctor of Philosophy 
 
May 2012  
Copyright Notice 
 
The copyright of this thesis vests in the University of the Witwatersrand, 
Johannesburg, South Africa, in accordance with the University’s Intellectual Policy. 
 
No portion of the text may be reproduced, stored in a retrieval system, or transmitted 
in any form or by any means, including analogue and digital media, without prior 
written permission from the University. Extracts of or quotations from this thesis may 
however, be made in terms of Section 12 and 13 of the South African Copyright Act 
No. 98 of 1978 (as amended), for non-commercial or educational purposes. Full 
acknowledgement must be made to the authors and the University. 
 
An electronic version of this thesis is available on the Library webpage 
(www.wits.ac.za./library) under “Research Resources” 
 
For permission request, please contact the University Legal Office or the University 
Research Office (www.wits.ac.za).   
 ii
Declaration 
 
I declare that this thesis is my own work. It is being submitted for the degree of 
Doctor of Philosophy at the University of the Witwatersrand, Johannesburg. It has not 
been submitted before for any degree or examination at this or any other University. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
Edmore Marinda     28 Day of May 2012 
 
 iii
Abstract 
Measuring HIV incidence has proved challenging over the years. A number of 
serological HIV assays have been proposed, and among these, the BED Capture 
Enzyme Immunoassay (CEIA) is one of the more widely used. Although the assay 
performs well among known seroconverting panels, it has been shown to classify 
some long term infected patients as being recently infected. Information on the 
performance of the BED assay among low CD4 cell count patients and those on anti-
retroviral therapy is limited. The risk of onwards transmission of HIV has been 
reported to be elevated around the seroconversion period compared to the chronic 
stage of infection.  RNA viral load has been reported as the strongest predictor of HIV 
transmission compared to other HIV markers.  Understanding how these markers 
influence the relationship between the likelihood of being recently infected and the 
BED assay might help in understanding some of the shortcomings of the BED assay. 
The main aim of this study was to understand the properties of the BED assay. The 
performance of the BED assay among advanced HIV disease patients and the 
influence of ART on BED levels once patients started treatment was investigated. The 
BED assay and CD4 cell count were used to quantify the risk of in utero and intra-
partum transmission to their infants among women believed to have seroconverted 
during pregnancy. The influence of viral load, haemoglobin and mid-upper arm 
circumference was investigated on the relationship between the probability of being 
recently infected and BED ODn levels.  
 
Methods   
Cryopreserved plasma samples from HIV patients on the national antiretroviral 
treatment (ART) rollout programme at Tygerberg Hospital HIV clinic, South Africa, 
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were used to investigate the effect of ART on BED ODn levels once patients 
commenced treatment. Mixed effect logistic regression models accounting for 
multiple readings per patient were used.  
To investigate the risk associated with seroconversion during pregnancy HIV 
seropositive women who had just given birth were classified into mutually exclusive 
groups according to their likelihood of having recently seroconverted using BED and 
CD4 cell count levels.  Multinomial logistic regression models adjusting for other 
factors were used to assess the risk of MTCT in utero and intra-partum infection 
comparing these groups.  
To investigate the relationship between BED ODn levels and the probability of being 
recently infected, BED data from known HIV infected women and women who 
seroconverted over a 2 year period was used.  Fractional polynomial regression 
models that allow for non-linear functions to be fitted were used, and the influence of 
viral load, haemoglobin and mid-upper arm circumference was assessed through 
multi-variable models. Data from the Zimbabwe Vitamin A for Mothers and Babies 
(ZVITAMBO) project, a double blinded treatment-placebo trial was used for these 
last two objectives.  
Results  
Patients with very low CD4 cell counts were more likely to test false recently infected 
according to the BED assay than other patients. ART changed BED ODn kinetics 
among HIV patients on treatment. Over half of advanced disease stage patients were 
likely to be classified as being recently infected according to the BED assay 2 years 
into ART treatment.  
 v
Women who seemed to have seroconverted during pregnancy had elevated risk of 
transmitting HIV in-utero compared to chronic HIV patients. BED and CD4 cell 
count were not predictive of risk of intra-partum infections attributed to 
seroconversion during pregnancy. 
The relationship between the probability of being recently infected with HIV and  
BED ODn levels was described better using Fractional Polynomial regression models 
than using a linear model in BED ODn or a model in which the BED ODn was 
categorised.  Viral load and haemoglobin were important independent predictors of 
incident infections.   
Conclusions 
If the BED assay is to be used for HIV incidence estimations patients on ART should 
be accounted for. The BED assay together with other HIV serological markers can be 
used as prognostic tools to assess the risk of HIV transmission.  
The risk of in-utero transmission of HIV is higher among women who seroconvert 
during pregnancy.  Repeat HIV testing among pregnant women may help in 
identifying women who seroconvert during pregnancy, and these women will benefit 
from Prevention of Mother-to-Child transmission (PMTCT) programmes.  
It was found that additional markers such as viral load and haemoglobin did not alter 
the relationship between the probability of having been recently infected and BED 
ODn.  
 
Keywords:  BED, IgG, HIV-1, HIV incidence, in utero, intra partum, seroconversion, 
fractional polynomials 
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CHAPTER ONE 
 
INTRODUCTION  
 2
1. Introduction 
The Human Immunodeficiency syndrome (HIV) epidemic has increased to an 
estimated 25 million infections worldwide, with 80% of these infections in Sub-
Saharan Africa. The United Nations program for HIV/AIDS (UNAIDS) estimated 
that 2.6 million new HIV-1 infections (range 2.3 – 2.8 million) occurred in 2009 
worldwide, translating to 7 119 new infections a day. One million eight hundred 
thousand (range 1.6 million – 2 million) of these new infections were in Sub-Sahara 
Africa [1]. Paediatric HIV/AIDs has reversed substantial gains in child survival 
achieved earlier as a result of successful immunization and other programs. Among 
breastfeeding populations without anti-retroviral prophylaxis, it was estimated that in 
utero transmission contributed 23%, intra-partum 65% and breastfeeding between 12 
– 14% of new HIV infection in infants [2-3].  Vertical paediatric transmission can be 
reduced to below 4% if current guidelines on anti-retroviral prophylaxis are followed 
[4]. The 2010 South African guidelines on Prevention of Mother-to-Child 
transmission of HIV (PMTCT) state that all HIV infected women who are not already 
on lifelong antiretroviral (ART) treatment should be initiated on Zidovudine (AZT)  
starting at 14 weeks gestation until the onset of labour. At the onset of labour, these 
mothers should get Single Dose Nevirapine (sdNVP) and AZT 3 hourly until delivery. 
The same women get Tenofovir (TDF) and Emtracitabine (FTC), while their infants 
are initiated on Nevirapine (NVP) for 6 weeks or for the duration of breastfeeding. 
Mothers who are not on lifelong treatment are assessed at 6 weeks post delivery to 
determine whether they need lifelong ART. Pregnant women who are already on 
lifelong treatment  continue on their ART regimen during and after delivery, and their 
infants are put on NVP for 6 weeks after birth [5]. There are still problems however in 
rolling this out to all eligible pregnant women partly because some women do not 
 3
know their HIV status and/or because some women have no access to antenatal 
services.  
 
Cumulative disease incidence is defined as the proportion of people in a well defined 
population that acquire the condition of interest in a defined period of time.  It is 
relatively straightforward to test and measure HIV-1 prevalence, which is the 
cumulative number of cases (both new and old), but measuring incidence is 
challenging, resulting in scarcity of HIV-1 incidence data. Methods for measuring 
HIV-1 incidence have largely been unsuccessful or too expensive for the most 
affected areas.  As much as 30% of primary HIV infection remains undiagnosed, thus 
the extent of new infections may be poorly defined [6-7]. Although changes in 
prevalence may give indications of trends in HIV-1 incidence, this does not guarantee 
accurate or reliable results, because HIV prevalence in cohort studies besides 
reflecting changes in incidence also show changes in other population factors such as 
migration, deaths and aging as well as survey coverage [8]. A considerable number of 
Sub-Saharan countries (29 countries), have reported no incidence data at all, while in 
other countries that including Benin, the Democratic Republic of Congo and Rwanda 
the data are outdated [9].  
 
Simple and valid ways of estimating HIV incidence such as the use of cross-sectional 
assays would greatly improve this situation. Sub-Saharan Africa, one of the poorer 
regions of the world, has the highest burden of HIV-1, making it extremely important 
that a simple and practical method of identifying recently infected persons is 
available. This will help in monitoring and controlling the spread of the disease.  
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1.1 Literature Review 
1.1.1 Importance of reliable estimates of HIV Incidence 
It is important to get reliable and timely estimates of HIV-1 incidence because 
information on recent infections is used for estimating HIV-1 trends. The impact of 
prevention and intervention programs can be evaluated by using information on new 
infections that occur over the intervention period [10]. Incidence data are required for 
identifying and selecting appropriate cohorts in preparation for vaccine trials and for 
microbicide trials [11-14]. A valid methodology for estimating HIV-1 incidence from 
cross-sectional surveys would be valuable for planning randomised controlled trials; 
specifically, for doing sample size calculations, as well as obviating the necessity for 
extended follow-up prior to the trial. Reliable data on the number of new HIV-1 
infections is of help in identifying high risk groups, so that targeted educational 
interventions can be implemented to maximize benefits [10, 15]. There is thus a need 
to strive to improve HIV intervention programs by combining proven effective 
methods, as well as the need to identify high incidence populations in which to 
efficiently evaluate these methods. 
 
Incidence screening methods would provide an entry point for identifying individuals 
for investigating characteristics of viral subtypes being transmitted. Patho-physiology 
and/or pharmacotherapy studies require the enrolment of newly infected individuals 
[10].  
 
Although current HIV-1 laboratory assays are neither sensitive nor specific enough to 
clinically identify new infection, available assays may be used for screening for high 
risk individuals, thus minimizing onward transmission. For example HIV incidence 
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assays that can be applied cross sectionally would have a large impact in public heath 
surveillance programmes. These would provide the opportunity to get accurate and 
timely measures of recent transmissions, thus preventive programs can be targeted 
and evaluated properly. The future extent of the HIV disease can be predicted with 
better certainty and finite resources can be allocated more appropriately [16].  
Correctly diagnosing newly infected individuals mean effective antiretroviral 
treatment that reduces viral replication following primary infection can be initiated 
[17-18]. Early treatment is likely to reduce the establishment of tissue virus reservoirs 
and leads to better prognosis [19-21]. It is however unlikely that in resource 
constrained settings preference for treatment would be given to newly infected 
individuals rather than chronic cases that qualify for treatment under existing 
guidelines.  
 
1.1.2 Methods for measuring/estimating HIV-1 incidence 
The ‘gold standard’ for measuring HIV-1 incidence is through conducting 
longitudinal follow-up studies where an initially HIV-1 negative cohort is recruited 
and followed up with regular HIV-1 testing [8, 22-26]. Repeated cross-sectional sero-
prevalence studies have been used to estimate HIV-1 incidence, using the rate of 
change of the sero-prevalence curve over time [27].  Some researchers have used the 
number of reported AIDS cases in the youngest age groups (13-25 years) as a measure 
of HIV-1 incidence, because it is thought that these individuals have relatively short 
incubation time from infection to AIDS [28]. Mathematical models such as the 
‘backward calculation’ model that combines number of AIDS cases with the 
distribution of the incubation period to infer how many HIV infections occurred 
during specified time periods have also been used [29-30]. Biological methodologies 
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such as the ‘capture-recapture’ method have also been proposed, in which individuals 
are ‘tagged’, repeatedly sampled and tested resulting in identifying initially HIV-1 
negative individuals who become positive providing a numerator for incidence 
estimation [31-32].  
 
The majority of the methods mentioned above require measurements to be taken over 
a long period of time, which has major implications for both the cost and exact timing 
of the measurements [33].  Repeated cross-sectional sero-prevalence studies, for 
example, are logistically difficult to carry out especially in large populations.  It 
would therefore be beneficial to have methods of estimating HIV-1 incidence from 
cross-sectional surveys.  There are a number of laboratory assays that were developed 
to distinguish new from old HIV infections. These assays define and differentiate the 
duration (window period) of a transient state related to changing virologic or 
immunologic response observed in early infection such as the detection of the virus 
before antibody seroconversion or they detect characteristics in the initial antibody 
response that differ from those of established infection [30, 34-36].  
 
1.1.3 HIV-1 Incidence Assays 
The natural history of the Human Immunodeficiency Virus type-1 (HIV-1) has 
features that evolve over time which can be used to differentiate recent from long 
term infections, Figure 1 [35]. In the early stages of primary infection, HIV-1 antigen 
or nucleic acid is detectable. After seroconversion antibody response evolves and 
matures, thus antibodies are detectable [30, 35].  The majority of HIV-1 laboratory 
assays are designed to detect antibodies, to identify antigen, to detect/monitor viral 
nucleic acids or estimate T-lymphocyte counts. Antigen tests and nucleic acid 
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detection methods are useful as an early detection tool in the period immediately 
following contact with an infected person. For HIV-1 diagnosis to be accurate, 
detection tests should be effective in identifying HIV-1 antibodies, and not antibodies 
directed to other infectious agents that may be antigenically similar. Antigens used in 
HIV-1 diagnostic tests should be appropriately specific, and these are normally 
purified antigens from viral lysates, or antigens produced through recombinant or 
synthetic peptides technology [10].   
 
Fig-1:A schematic diagram showing various parameters that define early HIV-1 infection. HIV-1 RNA and p24 
detection are useful in pre-seroconversion period while several antibody-based parameters are useful in post-
seroconversion period [15].  
 
Table 1 below lists some laboratory assays that have been developed, or are currently 
under investigation, for measuring HIV-1 recent infection. The assays can be 
classified into pre-seroconversions and post-seroconversion assays. 
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1.1.3.1 Pre-seroconversion tests 
The detection of HIV-1 RNA or p24 antigen in the absence of specific antibodies 
(Ab) indicates primary HIV infection (PHI), and this has been used to indicate new 
infections [19, 21, 37-40]. This acute or primary HIV-1 infection period can be 
diagnosed by p24 antigen or viral RNA via Polymerase Chain Reaction (PCR - RNA), 
and during this period symptoms of the acute retroviral syndrome occur [30, 38, 40-
42]. The duration during which RNA/p24 appears without antibodies is very short (~ 
1-2 weeks), thus limiting the practical use of RNA or p24 in incidence estimation [10, 
43]. For this assay to give accurate estimates of HIV incidence, a large number of 
HIV negative people would have to be tested and/or the incidence rate should be 
relatively high, more than 5% per year [28]. Testing for HIV-1 primary infection 
using these techniques is technically complex, expensive, and requires testing of the 
negative population.  This method is thus not suitable for wide scale implementation 
for determination of HIV-1 incidence [15, 44].  
Table 1 Assay for recent HIV infection [15] 
Assay Test for: Window Interval  
  From To duration 
HIV - RNA Plasma RNA RNA+ seroconversion ~ 19 days 
HIV p24 Plasma p24 P24+ seroconversion ~ 14 days 
LS-EIAs HIV Ab titer seroconversion Titer cutoff 130 – 170 days 
BED - CEIA HIV Ab/total IgG seroconversion Ab proportion 
cutoff 
153 – 187 days 
Avidity HIV Ab avidity seroconversion Avidity cutoff Variable 
Affinity HIV Ab affinity seroconversion Affinity cutoff Variable 
IgG3 isotype IgG3 anti-HIV Ab seroconversion Undetectable 
IgG3 Ab 
~ 80 days 
LS – EIAs, less sensitive – enzyme immunoassay;  
BED – CEIA, BED – capture enzyme immunoassay 
 
1.1.3.2 Post seroconversion test 
A number of tests that measure changing levels of antibodies (Ab) have been 
developed. The tests require relatively few individuals since only HIV-1 infected 
individuals are tested. They rely on the concept of a ‘window period’ which is the 
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time period sero-positive people stay below a pre-defined threshold on the test 
following seroconversion.  
 
The Less-Sensitive Enzyme Immunoassay (3All -LS EIAs) or detuned assay identifies 
persons in the early infection period when antibody titre is increasing but before 
peaking with persistently high antibody response [30, 45]. Among individuals testing 
positive to a standard ELISA test, tested blood specimens from newly infected 
individuals are reactive on the sensitive part of 3A11-LS but not on the less sensitive 
part of the assay, and thus are classified as recently infected. Individuals reactive on 
both the sensitive 3A11-LS and 3A11-LS less sensitive part are classified as long 
term infected. The 3A11-LS assay was assessed in subtypes B and E and great 
variation was found in the window periods for these subtypes.  Parekh et al. reported 
that 4% of participants (subtype E) remained below the threshold for recent infection 
on the LS EIA two years after seroconverting [46]. In the same study 8.7% of AIDS 
patients were also misclassified as recently infected by the assay. The wide use of the 
3A11 LS has been limited because it is not easily available, it needs specialised 
laboratory expertise and it needs dedicated equipment, and it does not perform as well 
in non-B subtypes of HIV [46]. 
 
Other tests that measure antibody activity have been studied. Measurement of 
antibody affinity, which is the strength of the reaction between an antigenic 
determinant and a single combining site on the antibody, is complex and not suitable 
for high throughput, while the avidity assay which measures the binding strength of 
antibodies to multiple antigenic determinants on natural antigens have largely 
remained in-house tools. Immunoglobulin M (IgM) is an antibody isotype that is 
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detectable early, but it has a short duration and is of variable intensity [47-51]. One 
study showed detection of IgM in patients with long term infection, which was 
probably a result of periodic viremia and antigenic stimulation [50], thus making 
detection of specific IgM an unreliable marker of recent HIV infection. 
 
1.1.3.3 BED Capture Enzyme Immunoassay (BED CEIA)  
The BED capture-enzyme immunoassay (BED CEIA) quantitatively reflects the 
proportion of Immunoglobulin G (IgG) HIV-1 antibody, and this proportion gradually 
rises and levels off in the first year of infection. The BED assay is performed in a 
single well, EIA format and, unlike other assays, is suitable for high throughput 
testing, with up to 96 samples being tested at one time.  The IgG BED CEIA is 
suitable for different HIV-1 subtypes because it was designed to include a peptide 
with divergent sequences from the immunodominant region of the trans-membrane 
protein, gp41 [35]. 
  
Individuals who are seropositive and test below a given threshold of the BED 
normalized optical density (ODn) are classified as recently infected and those who 
test above the threshold are classified as long term infected [35]. The window period 
of the BED assay, the time following seroconversion after which infections are no 
longer considered to be recently infected varies with subtype, and is estimated to be 
between 153 days (for subtype B and E) and 187 days (for subtype C) [35, 52].  An 
assay such as BED  has a reasonably long window period thus providing  a useful 
dynamic range for distinguishing recent from long term infections [35]. 
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Although the BED assay is commercially available and has been widely used, [34, 52-
56] it has been shown to overestimate HIV incidence as a proportion of subjects who 
in fact have long term infections, falsely test positive as being recently infected [34, 
36, 52, 57].    
 
Non-progressors on the BED assay are individuals whose proportion of HIV-1-
specific IgG never rises above the recency threshold within the window period, while 
regressors are individuals who despite being HIV-1infected for a long time have BED 
ODn values that are below the cutoff threshold after having previously progressed 
above it. Viral suppression due to immune reconstitution once antiretroviral treatment 
(ART) starts, concurrent infections, which are non-ignorable in the most affected 
countries, and late-stage HIV disease are some of the suggested biological reasons 
that may cause BED ODn levels of long term infected patients to fall below the 
threshold cutoff levels [57].  
  
1.2 Problem statement and Rationale 
It has been reported that BED produced HIV incidence estimates were 2-3 times 
higher than those derived from follow-up of negative cohorts or derived from 
prevalence surveys [34, 36, 52].  Specimens of 456 individuals who had AIDS from 
the USA and Thailand were tested using the BED CEIA assay, and 4.38% were 
classified as being new infections. A further 1.7% out of 178 non AIDS patient who 
had been infected for more than a year registered as recently infected in the same 
study. It was observed in this study that RNA viral loads differed by sub-type, with 
individuals presenting with sub-type E having relatively higher viral load three 
months after infection than those with sub-type B [35]. In another study in Rwanda 
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and Zambia individuals misclassified as recently infected by the BED CEIA assay 
after a year of infection had lower plasma viral load compared to those correctly 
classified as long term infected (median copies/ml 14 773 versus 93 560; p = 0.02). In 
the same study clinical presentation and HIV-1 sub-type was not associated with BED 
misclassification in seroconverter samples [34]. In an intravenous drug usage (IDU) 
study of 594 individuals in Bangkok, 17.3% [95% CI 12.8 to 24.2] of participants 
were estimated by BED to have been recently infected in the previous year, almost 
twice the observed incidence of 9.0 % [95% CI 6.7 to 11.9%] per year [35]. A study 
in Zimbabwe among women known to have been infected in the first two years post-
partum gave BED derived HIV-1 incidence estimates of 4.1 [95% CI 3.3 to 4.9] 
infections per 100 susceptible persons per year.  When the BED assay was used on all 
sero-positive post-partum women regardless of known timing of infection, HIV 
incidence was estimated to be 7.6 infections per 100 susceptible persons per year. 
This estimate was  2.2 times higher than the longitudinal follow-up estimates of 3.5 
infections [95% CI 2.8 to 4.2] per 100 person years of follow-up [52].  
Serial serological panels of known HIV seroconvertors with known date of 
seroconversion are used in validating assays such as the BED assay. Optimal cutoffs 
for defining timing of infection as well as estimating assay window periods are 
determined from these panels. Only recently infected patients with panel data are used 
in validating these assays. In the ZVITAMBO study, initially HIV negative post-natal 
women were followed up and regularly tested for HIV, every 3 months for up to 2 
years [52]. The timing of HIV seroconverstion was estimated using the last negative 
and first positive ELISA tests.   
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With increased availability of antiretroviral treatment for HIV infected individuals,  
more and more people are living longer, thus the pool of individuals who could be 
wrongly classified as recently infected by the BED assay is likely to increase. Anti-
retroviral drugs result in immune reconstitution, thus various immunological markers 
including BED levels may change with ARV treatment. It is important to investigate 
how ART affects BED ODn levels among patients starting treatment and on ART.  
 
The risk of mother-to-child transmission through breast feeding has been shown to be 
higher if a woman seroconverts during breast feeding compared to a woman who has 
been infected for a long time [58]. Seroconversion is associated with high levels of 
the HIV virus and higher viral load has been reported as a risk factor for all modes of 
HIV transmission [59-63]. It is not clear if the risk of transmission of HIV from the 
mother to her unborn child (in utero infection) increases if the mother seroconverts 
during pregnancy. Reported risk factors for in utero infection include high viral load 
and low CD4 cell count among others, but little data is available on the risk of MTCT 
associated with maternal seroconversion during pregnancy. It is not easy to identify 
recently infected pregnant women because of infrequent testing during this period.   
 
It is important to understand the mathematical form of the relationship between the 
probability of being recently infected and the BED ODn, and how this relationship 
may be affected by other serological markers such as viral load, CD4 cell count and 
haemoglobin.  Slow HIV disease progressors, sometimes referred to as HIV 
suppressors, have been known to present with low viral loads, but there are few 
results on the relationship between BED ODn and other markers such as 
haemoglobin. Understanding the relationship between the probability of recent 
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infection and BED ODn, and how this relationship may be altered by viral load, 
haemoglobin, and CD4 cell count may help in understanding and refining new testing 
algorithms. Understanding the properties of the BED CEIA assay and how the assay 
is associated with other serological markers of HIV-1 infection may shed light on 
some of the shortcomings of the assay. 
 
This PhD project aims to investigate the properties of the BED assay. The project 
investigated the performance of the BED assay among patients on ARV treatment, 
and how this performance change with length of time on ARVs. The project showed 
how the BED assay in conjunction with CD4 cell count could be used as a surrogate 
marker of recent infection in order to investigate whether women infected during 
pregnancy were at increased risk of transmitting HIV to their infants in-utero and 
intra-partum. The relationship between the BED assay and the likelihood of being 
recently infected was investigated among HIV infected patients. The effect of other 
markers viral load, haemoglobin and mid upper arm circumference (MUAC) was 
explored.  
 
 1.3 Aims and Objectives 
1.3.1 General Aims 
The aim of the study was to understand the association between BED Optical Density 
(ODn) values and other HIV-1 markers such as viral load, and haemoglobin, as well 
as how anti-retroviral treatment affects BED ODn values. The project investigated the 
relationship between BED and other proxies of disease such as mother-to-child HIV-1 
transmission.  The next three chapters presented as standalone publications address 
the following three main objectives of the research thesis.  
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1.3.2 Specific Objectives 
1. To investigate the performance of the BED assay in patients with advanced 
disease and how the assay performs among patient on antiretroviral treatment.  
2. To estimate the risk for in utero and intra-partum HIV-1 infection by combining 
the BED CEIA and CD4 cell count.    
3. To investigate and describe the functional form of the relationship between the 
probability of being recently infected and BED values and how this relation is 
affected by other markers such as viral load, haemoglobin and maternal mid-upper 
arm circumference.  
 
1.3.3 Methods 
1.3.3.1 Study samples and data: 
The data used in this research came from the Zimbabwe Vitamin-A for Mothers and 
Babies (ZVITAMBO) project, Harare, Zimbabwe and from Tygerberg Hospital in 
Cape Town, South Africa.  
 
1.3.3.2 ZVITAMBO data and samples  
The ZVITAMBO Project trial, which is described in detail elsewhere [64], was a 
large randomized double blinded placebo controlled clinical trial whose main 
objective was to measure the impact of a single large post-partum dose of vitamin A 
given to mothers and/or neonates on a number of clinical outcomes; infant mortality 
and morbidity, Mother-to-Child-Transmission (MTCT), incident HIV-1 infection 
among women and maternal morbidity among other outcomes. Fourteen thousand, 
one hundred and ten (14 110) postpartum mothers and their newborn babies were 
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enrolled within 4 days of delivering a single baby. The study started recruitment at 14 
maternity clinics in Harare, Zimbabwe in November 1997 and ended in January 2000. 
Various methods, including structured questionnaires were used to collect data. 
Mother-infant pairs were followed up at 6 weeks, 3 months, and then every 3 months 
for up to 12 or 24 months.  
 
1.3.3.2.1 Maternal Serological samples 
Mothers’ blood was collected into EDTA and plain tubes at recruitment. Mothers 
EDTA samples were then stored at ~ 20o C and all other samples at ~ 10o C before 
being processed within 2 hours of phlebotomy. Maternal plasma and an aliquot of 
serum were stored at - 70o C. The remaining serum was immediately used to test for 
HIV-1 using a rapid test [Immuno Chemical Laboratories (ICL) Path Seattle, 
Washington] and then batched for subsequent ELISA testing. The ICL did not have 
good enough sensitivity and specificity for diagnostic purposes, but was used to 
identify probable infected samples so that CD4 cells could be enumerated within 48 
hours of phlebotomy (Faccount, Becton Dicknson International, Erembodegem, 
Belgium). Maternal sera were tested for HIV by two ELISA assays (HIV 1.0.2 ICE: 
Murex Diagnostic, Edenvale, South Africa, and GeneScreen HIV 1 / 2: Sanofi 
Diagnostics Pasteur, Johannesburg, South Africa) run in parallel. Discordant ELISA 
results were resolved by a Western Blot assay (HIV Blot 2.2: Genelabs Diagnostics 
SA, Geneva, Switzerland). Among mothers who tested HIV positive at recruitment, 
serum RNA concentration (viral load) was measured (Roche Amplicor HIV-1 
Monitor test version 1.5 Roche Diagnostics, Alameda, CA, USA). Haemoglobin was 
measured at baseline for all women recruited from 1 October 1998 to the end of the 
study (60% of total samples) on a drop of blood from the EDTA tube using HamoCue 
 17
hemoglobinometer (HemoCue, Mission Viejo CA) on the same day of collection. 
Stored sera for all HIV-1 ELISA positive women were run on the BED IgG (cat. Bo 
98003; Calypte Biomedical Corporation, Lake Oswego, OR USA). Results of samples 
with BED ODn values greater than 1.2 or less than 0.8 were returned as final 
readings. BED results between 0.8 and 1.2 were rerun. The last result was taken as the 
final result if the resultant rerun was above 1.2; otherwise the sample was run in 
triplicate. The median value of the three readings for this third level run was taken as 
the final reading.  
 
There were 9562 HIV-1 ELISA negative women at recruitment of whom 352 later 
tested ELISA positive. All sera from these 352 seroconverting women were run on the 
BED CEIA assay. There were 4595 baseline HIV-1 ELISA positive women in the 
ZVITAMBO study.  BED CEIA was run at baseline, six months and at 12 months for 
sera from these women who tested positive at baseline.   
 
1.3.3.2.2 Baby Serological samples 
Cell pellets (Roche Diagnostics Systems, Alameda, CA) and plasma were prepared 
from whole blood collected at baseline and follow-up visits and stored at –70°C for 
babies born to HIV-1 positive women. At the end of all patient follow-up, the last 
available sample from each infant was tested (pellet by Roche Amplicor version 1.5 
qualitative DNA PCR assay [Roche Diagnostic Systems] for samples collected prior 
to 18 months; serum by GeneScreen ELISA for samples collected after 18 months). If 
this sample was negative, the child was classified as HIV-negative; if it was positive, 
then earlier samples were tested to determine timing of infection. 
 
1.3.3.3 Tygerberg data and samples 
Plasma samples from 501 HIV-1 infected patients enrolled for the South African 
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National treatment programme at the Tygerberg Hospital HIV clinic, Cape Town, 
South Africa, were used to investigate the association between BED and being on 
antiretroviral therapy (ART). All available samples beginning from just before the 
initiation of ART and continuing up to 31 months after starting treatment were tested 
using the BED assay.  The testing protocol was similar to that used in the 
ZVITAMBO study and followed the instructions of the manufacturer of the test kit.   
 
The thesis comprises three papers which are briefly described in the following 
sections and then presented in detail in chapters 2-4.  Chapter 5 summarizes the 
results of the research and suggests further research on the topic.  
 
1.3.4.1 Paper 1  Significantly diminished long –term specificity of the BED 
Capture Enzyme Immunoassay among patients with very low CD4 count and 
those on antiretroviral therapy. 
In chapter 2, we investigate the specificity of the BED assay among long term 
infected patients about to start ART treatment. The performance of the assay is also 
assessed once these patients commence treatment, using samples collected at 6 
months, 12 months, 18 months and at 2 years after initiation of ART treatment. Anti-
retroviral treatment has been shown to change specific HIV-1 antibody levels and it is 
likely that it also affects IgG levels [65-66]. In this study archived  samples from 
patients referred to the Tygerberg hospital in Cape Town, South Africa for ART as 
part of the South African ART Roll Out program were used. Those presenting with 
BED ODn values below 0.8 were classified as false recently infected, while those 
with BED values 0.8 or higher were classified as long term infected. Patients’ BED 
levels were measured over a 2 year period once ART had commenced. Logistic 
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regression models were fitted using as outcome low vs  high BED levels; multiple 
visits during the two-year follow-up were accounted for by the use of population 
average mixed effect models, allowing for both random slopes and random intercepts.  
Viral load and CD4 cell count were used as explanatory variables in addition to time.  
 
1.3.4.2 Paper 2  In utero and intra-partum HIV-1 transmission and acute 
HIV-1 infection during pregnancy: Using the BED Capture Enzyme 
Immunoassay as a surrogate marker for acute infection 
Primary HIV-1 infection may increase the risk of HIV-1 transmission to the unborn 
child both during pregnancy (in utero) and during delivery (intra-partum). Baseline 
data for women who tested HIV-1 positive from the ZVITAMBO Project was used 
for this paper. To compare the risk of in utero and intra-partum infection between 
recent infection and chronic infection, we fitted both unadjusted and adjusted 
multinomial logistic regression models, with an outcome variable with three levels 
namely in utero, intra-partum transmission or PCR negative at 6 weeks. Women were 
classified into 6 distinct exposure groups using two BED ODn cut offs (< 0.8 and ≥ 
0.8) and three CD4 cell counts cut offs (< 200, 200 – 350 and ≥ 350). This paper 
investigated how the BED assay can be applied to stored samples in order to provide 
further evidence of the increased risk of MTCT when a woman is infected during the 
course of her pregnancy.  
  
 
1.3.4.3 Paper 3  Modelling the BED Capture Enzyme Immunoassay (CEIA) 
in new HIV infections     
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In chapter 4, we investigate the functional form of the relationship between the 
probability of being classified as recently infected and the BED ODn readings. 
Fractional polynomial (FP) models are found to be useful in modelling this 
relationship [67-68]. The impact of including RNA viral load, haemoglobin and mid-
upper arm circumference on this relationship is also investigated. The data used to 
answer this question came from the ZVITAMBO project, (described above and in the 
paper). Briefly, women who tested HIV-1 positive at the time of recruitment and 
women who seroconverted during the post-partum follow-up period were considered 
for the study. Two populations of women were used in the analysis, with the 
population being defined by the degree of certainty in classifying the women as either 
recent seroconvertors or long term-infected respectively. To be included in either 
population, women had to have complete data on BED, viral load, haemoglobin and 
MUAC; complete data was required to enable the comparison of different statistical 
models.  We used the logit link, with baseline positive women classified as long term 
infected (coded 0), and known seroconverting women as recently infected (coded 1). 
Three logistic regression models where used; the logit of recent infection fitted on: 
1. Linear regressors BED, viral load, haemoglobin and MUAC. In this model we 
fitted:  
݈݋݃݅ݐሺ݌௜ሻ ൌ 	ߚ଴ ൅	ߚଵ ∗ ܱܦ݊௜ ൅	ߚଶ ∗ ܸܮ௜ ൅	ߚଷ ∗ ܪܤ௜ ൅ ߚସ ∗ ܯܷܣܥ௜ 
where  i = 1 to n indexes the women used in the analysis and ODn denotes 
BED ODn, VL denotes viral load, HB denotes the haemoglobin and MUAC 
denotes the mid-upper arm circumference, all fitted as continuous variables.   
2. Regressors BED, viral load, haemoglobin and MUAC were fitted in the 
logistic regression model as categorized variables, i.e. 
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for i = 1 to n, and j = 1 to (r -1) for (r-1) BED ODn dummy variables, k = 1 to (s – 1) 
for (s – 1 ) dummy variables for viral load, l = 1 to (t – 1) for (t – 1) haemoglobin 
dummy variables, and m = 1 to (u – 1) for (u – 1) dummy variables for MUAC.   
3. All regressors, BED ODn, viral load, haemoglobin and MUAC were allowed 
to take any form including non-linear forms using fractional polynomials. In 
the model the linear part of the logit(pi) is allowed to assume a nonlinear 
function;  
ߟ௜ሺܺ; ࢼ; ࢖ሻ ൌ ߚ௢ ൅ ߚଵܺ௣భ ൅	ߚଶܺ௉మ൅	. . ൅ߚ௥ܺ௉ೝ  
where βi are regression parameters,  ܺ௣೔ ൌ 	ܺ௣೔݈݋݃௘ሺܺሻ if pj = pj-1 or Xpj if pj ≠ pj-1, 
and Xp denote the Box-Tidwell transformation defined as Xp if pj ≠ pj-1 andܺ଴ 	≡
	݈݋݃௘ሺܺሻ	[69]. A restricted list of integers and non-integers: (-2, -1,-0.5,0,1,0.5,1,2,3 ) 
such that p1 < … < pr , have been proposed for values of pi , and these have been 
shown to be sufficient to cover a wide range of linear (when p = 1) and non-linear 
functions commonly encountered in medical epidemiology [67]. A wide range of 
link(η) functions that include the identity, logit, probit, poisson, negative binomial 
among others can be fitted. The logit link was used in this study. The fitted 
probability of being recently infected was obtained from the expression: 
݌̂݅ ൌ 	 ݁
ࢄ࢏ᇱࢼ෡
1 ൅ ݁ࢄ࢏ᇱࢼ෡  
where X’ is a row vector of regressors for the ith observation and ߚመ  is a vector of fitted 
coefficients. Univariable models for outcome recent and regressor BED and 
multivariable models adjusted for viral load, haemoglobin and MUAC were fitted.  
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All models were fitted using maximum likelihood methods. The likelihood ratio test 
and the Akaike Information Criterion (AIC) were used to choose between linear, 
categorical and fractional polynomial models [70]. Model fit was assessed using the 
Hosmer-Lemeshow Goodness-of-Fit test [71].  
 
1.3.5 Statistical methods and Data Management 
ZVITAMBO data were stored in Visual Dbase, a relational database that links 
laboratory information with follow-up data. Additional data from Tygerberg were 
stored in MicroSoft Excel. Data cleaning was carried out in both Visual Dbase and 
during analysis. Data analysis was carried out using STATA release 10 
(STATACORP version 10; College Station, TX). In general estimates were reported 
with 95% confidence intervals, and where statistical tests were done, the 5% 
significance level was used.   
 
1.3.6 Ethics 
The ZVITAMBO Project obtained ethical clearance from the Medical Research 
Council of Zimbabwe, Johns Hopkins Bloomberg School of Public Health Committee 
on Human Research, and Research Ethics Committee of the McGill University Health 
Centres (CHR#H.22.96.06.17.B , REC#96-064, MRCZ/A). Ethical approval for the 
Tygerberg study was granted by the Committee for Human Research of the Faculty of 
Health Sciences, Stellenbosch University (project number N07/06/137). The current 
study obtained ethical clearance from the University of the Witwatersrand’s 
Postgraduate Ethics Committee on Human research (clearance number M080224). In 
both studies patients provided written signed informed consent, and confidentiality 
was maintained as per standard laboratory protocols.  
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CHAPTER TWO 
SIGNIFICANTLY DIMINISHED LONG-TERM SPECIFICITY OF THE 
BED CAPTURE ENZYME IMMUNOASSAY AMONG PATIENTS WITH 
HIV-1 WITH VERY LOW CD4 COUNT AND THOSE ON 
ANTIRETROVIRAL THERAPY 
  
EPIDEMIOLOGY AND SOCIAL SCIENCE
SignificantlyDiminished Long-TermSpecificity of theBED
Capture Enzyme Immunoassay Among Patients With
HIV-1 With Very Low CD4 Counts and Those on
Antiretroviral Therapy
Edmore T. Marinda, MSc, MS,* John Hargrove, PhD,† Wolfgang Preiser, DTM&H, MRCPath,‡
Hannes Slabbert, MSc,‡ Gert van Zyl, MBChB, FCPath, MMed,‡ Jonathan Levin, PhD,§
Lawrence H. Moulton, PhD,k Alex Welte, PhD,†¶ and Jean Humphrey, ScDk#
Objective: To estimate the proportion who test as recent infections
by the BED capture enzyme immunoassay (BED) among patients
about to commence, and those receiving, antiretroviral therapy.
Design: Cryopreserved plasma samples from HIV patients on the
national antiretroviral treatment (ART) rollout program at Tygerberg
Hospital HIV clinic, South Africa, were tested using the BED assay.
Participants: Five hundred five patients qualifying for ART were
included in this study.
Method: All plasma samples from each patient were tested by BED.
Basic demographic data, HIV-1 viral load, and CD4 count results
were obtained from the laboratory database.
Main Outcome: The proportion presenting as false recently
infected is reported.
Results: Among patients, with presumed long-term HIV-1
infections, about to commence ART, 11.2% [95% confidence interval
(CI): 8.3 to 14.5%] tested recent by BED. The proportion was higher
among patients with CD4 counts ,50 cells per microliter [odds ratio
2.63, 95% CI: 1.39 to 5.00] and log10 HIV-1 viral load less than 4
[odds ratio 3.03, 95% CI: 1.05 to 9.09]. Proportions testing false
recent increased from 11.2% before ART to 17%, 25%, 38%, and
56% at 0.5, 1, 1.5, and 2 years, respectively, after ART initiation.
Conclusions: If the BED method is to be used for the accurate
estimation of HIV incidence from cross-sectional surveys, it will be
essential, before other statistical adjustment methods, to identify, at
least, all cases who are on ART and all those with CD4 counts , 50
cells per microliter. The more general remaining problem is the
unequivocal identification of all persons with long-term HIV
infections.
Key Words: BED, HIV-1, HIV incidence, IgG, specificity
(J Acquir Immune Defic Syndr 2010;53:496–499)
INTRODUCTION
Numerous attempts have been made to measure HIV-1
incidence in a timely and inexpensive manner.1–8 Although
some success has been achieved, obstacles still remain to
widespread use of these methods, especially in the developing
world, where such methods and technologies are most urgently
required.1,9 The most reliable way of measuring HIV incidence
is following up HIV-uninfected but susceptible cohorts,
measuring new infections over specified time periods. This,
however, is subject to a number of biases, is expensive, and
involves following up large numbers of people over long
periods of time.9–11
Accurate and timely measures of HIV incidence would
provide ways of evaluating impacts of interventions, estimat-
ing epidemiological trends in HIV studies, and providing
baseline measures at the start of clinical trials.4,10,12 Several
laboratory assays have been proposed for estimating HIV
incidence, with the BED capture enzyme immunoassay
(henceforth BED; Calypte Biomedical Corporation, Rock-
ville, MD) being one of the most promising. The assay
measures the changes in anti-HIV-1 immunoglobulin G (IgG)
activity relative to total IgG and is typically used to classify
individuals as HIV-1 recently infected or long term infected
depending on whether a normalized absorbance reading lies
below or above a preset optical density cutoff point (C).4,13 The
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time taken post-seroconversion for the BED’s optical density
to exceed C is termed the window period. The assay is easy to
perform, does not need specialized equipment, and has inbuilt
quality control.4,13 Several analytical methods have been
proposed to infer incidence from the distribution in a cross-
sectional survey of HIV-negative, recently infected, and long-
term infected individuals. These methods systematize, under
different assumptions, the intuitive idea that a cross-sectional
survey finding a large fraction of recently infected individuals
is indicative of a high incidence. Studies in the United States,
Asia, and Africa have however shown that estimates produced
using this assay are 2 to 3 times higher than those obtained
using prospective follow-up data.4,10,11,14 This is essentially
a consequence of the proportion of individuals who test as
recently infected, despite being HIV-1 positive for more than
twice the window period. A proportion of these are patients
who remain below the target threshold of the assay for all
times. Others may revert to being misclassified as recently
infected when they reach end-stage AIDS or on antiretroviral
treatment (ART).15 We studied the latter problems by
estimating the proportion testing as recent infections by
BED among patients immediately before, and while they were
undergoing, ART.
MATERIALS AND METHODS
Study Population
We used cryopreserved plasma samples from HIV-
infected (predominantly clade C) patients referred for ART to
the South African national rollout program at the Tygerberg
Hospital HIV clinic, Western Cape province, South Africa.
Most of the Tygerberg patients did not have evidence
of previous positive HIV test results. To qualify for ART,
HIV-seropositive patients had to have a CD4 count of less than
200 cells per microliter or had to suffer from an AIDS-defining
condition, both of which almost invariably imply long-
standing HIV infection. We therefore consider it safe to
assume that patients qualifying for inclusion in the ART
rollout program, that is, fulfilling the above-cited criteria, have
been infected for several years, that is, more than twice the
BED assay’s window period.11,14
All patients were assumed to have been ART naive
before enrollment at Tygerberg. Routine laboratory diagnosis
at the time included measurement of HIV-1 viral load (i.e.,
quantitative HIV-1 RNA in plasma using the NucliSens EasyQ
HIV-1 V1.1 system; bioMe´rieux bv, Boxtel, the Netherlands)
and CD4 count at baseline, that is, when enrolling for ART.
Once enrolled on ART, patients are normally monitored for
HIV-1 viral load and CD4 count at 6-month intervals. Residual
EDTA plasma specimens left over after routine HIV-1 viral
load testing has been performed are routinely stored in the
220°C specimen cryobank at the Division of Medical
Virology, National Health Laboratory Service Tygerberg.
Inclusion criteria for our study were being on ART and
at least 1 residual specimen being available in the cryobank.
All specimens were collected between January 14, 2004, and
August 3, 2006. Wherever available, serial samples were
selected; the first one taken at enrollment for ART and later
ones from the same patient at subsequent clinic visits. For
follow-up samples, the minimum duration of HIV infection is
determined by the time since the baseline sample. Ideally, we
tried to select samples at 12- and 24-month follow-up
intervals. However, due to suboptimal adherence to follow-
up schedules, many follow-up samples were obtained at
intermittent intervals, that is, 6 and 18 months.
All available cryopreserved plasma samples from each
patient were tested by the BED assay. Basic demographic data
and HIV-1 viral load and CD4 count results were retrieved
from the laboratory database. Viral load results were log10
transformed.
BED Testing
Cryopreserved plasma samples were thawed and then
immediately tested by the Calypte HIV-1 BED Incidence EIA
(IgG-capture HIV-EIA; BED-CEIA) strictly following the
manufacturer’s instructions (cat. no. 98003; Calypte Bio-
medical Corporation, Lake Oswego, OR).
BED measures levels of HIV-1–specific IgG antibodies
as a proportion of total serum IgG antibodies; it detects recent
seroconversion through low levels of HIV-1–specific IgG.
Specimens with normalized optical density (ODn = ODspecimen/
ODcalibrator) of less than 0.8 are classified as recent infections
and those with values of 0.8 or more as long-term infections.
According to the test kit insert, all samples with ODn values
of 1.2 or less must be retested in triplicate (confirmatory
testing); the median ODn value of the 3 repeats is then used to
classify the sample as recent (if ODn ,0.8) or long term (if
ODn $0.8).
We retested the first 81 samples with initial ODn values
#1.2. Of these, 47 had ODn values of #0.8 and 34 had ODn
values .0.8 and#1.2. Retesting did not change classification
in 70 of the 81 samples (86.4%). Four samples were classified
by retesting as long term despite an initial ODn #0.8 and 7 as
recent despite an initial ODn.0.8. The observed high level of
concordance between the initial and the confirmatory test
results is in line with the results of a previous evaluation by
Dobbs et al.13 We therefore decided to abandon retesting for
the remainder of the study as it resulted in negligible difference
on a population basis.
Statistical Methods
Data were entered into Microsoft Excel and exported to
STATA (STATACORP version 10; College Station, TX) for
analysis. Ninety-five percent confidence intervals (CIs) are
reported for all estimates. We used 5% significance levels for
all comparisons. The rate of false recent was estimated as
a percentage with 95% binomial CI. We used 2-tailed t tests or
nonparametric equivalents to compare BED recent versus
BED long term infected for continuous variables and x2 or
Fisher exact tests for categorical variables.
To investigate factors associated with false-recent BED
status before commencement of ART, multiple logistic
regression models were used. To investigate trends in BED
ODn values over the treatment period, we fitted random effect
multiple logistic regression models to account for repeated
readings for individuals over time.
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Ethics and Confidentiality
Ethics approval was granted by the Committee for
Human Research of the Faculty of Health Sciences,
Stellenbosch University (project number N07/06/137) and
the University of the Witwatersrand’s Postgraduate Ethics
Committee on Human research (clearance number M080224).
Confidentiality was maintained as per standard laboratory
protocol.
RESULTS
In total, 1061 samples collected from 505 patients were
analyzed with the BED assay. Not all patients had BED
readings at the first visit. There were 430 baseline BED ODn
readings and 433, 127, 31, and 9 readings at 0.5, 1, 1.5, and
2 years of follow-up, respectively. Of the 505 patients in the
study (median age 33 years), 132 (31%) were male (median
age 37 years, range 22–79 years) and 298 (69%) were female
(median age 32 years, range 18–58 years).
Proportion Testing as Recent HIV-1 Infections
Just Before Commencing ART
Univariate analysis provided an overall BED false-recent
rate of 11.2% (95% CI: 8.3 to 14.5%), independent of patient
gender and age (P = 0.67 and 0.16, respectively). Among
patients with CD4 counts below 50 cells per microliter, 18 of
89 (20.2%, 95% CI: 12.4 to 30.1) tested recent by BED
compared with 30 of 341 (8.8%, 95% CI: 6.0 to 12.3) of those
with higher CD4 counts (P = 0.002 for the difference).
In multivariate analysis with independent variables
log10 viral load (stratified above and below 4) and CD4
count (stratified above and below 50 counts/mL), patients with
low CD4 and low viral loads were 2.9 (95% CI: 1.5 to 5.6) (P =
0.01) and 3.8 (95% CI: 1.39 to 11.11) (P = 0.001) times more
likely to test BED false recent than those with high CD4 and
high viral loads, respectively.
Performance of the BED Assay When
ART Commences
In univariate analysis, the percentage of patients testing
recent by BED increased from 11.2% pre-ART to 17%, 25%,
38%, and 56% at 0.5, 1, 1.5, and 2 years, respectively, after
treatment commenced (Fig. 1).
After adjusting for CD4 count, stratified as above, the
odds of testing recent by BED, compared with the baseline
visit, were 2.1 (95% CI: 1.6 to 2.9), 3.5 (95% CI: 2.2 to 5.7),
6.8 (95% CI: 3.0 to 15.7), and 12.2 (95% CI: 3.2 to 46.1) at
visits 0.5, 1, 1.5, and 2 years, respectively, after ART initiation.
The wide CIs for estimated odds ratios are a consequence of
sparse data for later time-points. Low CD4 count (below 50),
but not viral load, remained predictive of testing recent in
a random effect multiple logistic regression model.
DISCUSSION
Previously published analysis of data from the
AIDSVAX B/B vaccine trial and Zimbabwe Vitamin-a for
Mother and Babies Project (ZVITAMBO) studies showed that,
if the BED were to be at all useful for estimating HIV
incidence, it would be necessary to adjust for a proportion of
patients infected with HIV-1 for long periods of time (much in
excess of 1 year) who nonetheless continued to test as recent
infections by BED.11,14 In these 2 studies, there were, however,
few cases with CD4 counts below 50 cells per microliter and
nobody was on ART.
The present study shows that the proportion testing
recent increased significantly among pre-ART clients with
CD4 counts below 50 cells per microliter, and even more
sharply with time spent on ART, its value being significantly
raised only after 6 months on ART. This poses serious
problems because BED incidence estimates are very sensitive
to changes in the proportion of long-term false-recent cases.14
Moreover, as previously observed, patients with a log10 viral
load of 4 or less than 4 (i.e., ,10,000 viral copies/mL) were
more likely to test false recent than those with higher viral
loads.16 If the BED method is to be used for the accurate
determination of HIV incidence from cross-sectional surveys,
we must be able to identify, and classify as long-term
infections, cases who are on ART and/or have extremely low
CD4 counts. Failure to do so will lead to unknown, but
probably very large, errors in incidence estimates.
It is unclear why differences exist, between studies in the
same region and among people infected with the same clade of
HIV-1, in the proportion of long-term HIV-1 infections who
continue to test recent by BED. Suggested factors influencing
BED recency threshold include viral suppression, immune
reconstitution on ART, concurrent infections, and late-stage
HIV disease. Participants in the ZVITAMBO study were
generally free of life-threatening conditions at recruitment
(only 15/4495 HIV-1–positive individuals presented with CD4
count of less than 50 cells/mL), and a substantial number of
patients with AIDS-defining conditions were thus excluded.14
FIGURE 1. Percent false recent by BED as a function of time
since initiating ART. Vertical bars indicate 95% CI.
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In the Tygerberg study, conversely, patients either had to have
a CD4 counts below 200 cells per microliter and/or an AIDS-
defining condition to qualify for ART. Depending on the stage
of the HIV epidemic in the population, patients at the AIDS
stage are expected to be relatively fewer than those at other
stages. The false-recent proportion of 11.2% for all patients, or
8.8% for patients with CD4 counts of 50 cells per microliter or
above, in the Tygerberg study probably overestimates the true
false-recent ratio among long-term HIV-1 infections in the
population. (This problem would have been exacerbated if our
unverifiable assumption that all patients recruited into this
treatment center were ART naive was violated.) Conversely,
because ZVITAMBO excluded AIDS patients, it is possible
that the 5.2% figure from that study underestimated the true
proportion in the female population.
By contrast, the Africa Center study reports a false-
recent proportion of 1.7% among clients known to be infected
with HIV-1 for more than 1 year, much lower than other similar
clade C estimates.17 The study is one of the few that covers the
whole spectrum of HIV-infected individuals: both sexes,
different age-groups, and individuals at different HIV disease
stage. Further studies are clearly indicated to discover the basis
of the variability in the proportion of false-recent infections
between populations. Such studies must be based on
appropriate sample sizes and carried out in a variety of
situations to assess variations with geography, HIV subtype,
ART treatment, and other demographic factors. All factors that
potentially influence BED ODn threshold levels, such as CD4
count, viral load, ART, and coinfections, should be inves-
tigated and appropriately used to aid in the estimation of robust
HIV incidence estimates.
Algorithms that combine results of more than 1 test,
either sequentially or in parallel, thus improving predictive
values of the assay, could be used to improve incidence
estimates.1 But such protocols and the use of clinical
information to improve assay performance are unlikely to be
feasible in resource-constrained setting. The essential problem
in using the BED method to estimate HIV incidence thus
continues to lie in the lack of unequivocal identification of
persons with long-term HIV infections. If some alternative test
can be developed to achieve this end, it could be used with or
without other assays to render the statistical corrections
unnecessary, and this should be a primary research aim.11
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CHAPTER THREE 
IN UTERO AND INTRA-PARTUM HIV-1 TRANSMISSION AND ACUTE 
HIV-1 INFECTION DURING PREGNANCY: USING THE BED CAPTURE 
ENZYME-IMMUNIOASSAY AS A SURROGATE MARKER FOR ACUTE 
INFECTION. 
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Objective The BED assay was developed to estimate the proportion of recent
HIV infections in a population. We used the BED assay as a proxy
for acute infection to quantify the associated risk of mother-to-
child-transmission (MTCT) during pregnancy and delivery.
Design A total of 3773 HIV-1 sero-positive women were tested within 96 h
of delivery using the BED assay, and CD4 cell count measurements
were taken. Mothers were classified according to their likelihood of
having recently seroconverted.
Methods The risk of MTCT in utero and intra-partum was assessed comparing
different groups defined by BED and CD4 cell count, adjusting for
background factors using multinomial logistic models.
Results Compared with women with BED5 0.8/CD45 350 (typical of
HIV-1 chronic patients) there was insufficient evidence to conclude
that women presenting with BED<0.8/CD45 350 (typical of recent
infections) were more likely to transmit in utero [adjusted odds ratio
(aOR)¼ 1.37, 96% confidence interval (CI) 0.90–2.08, P¼ 0.14],
whereas women with BED<0.8/CD4 200–349 (possibly recently in-
fected patients) had a 2.57 (95% CI 1.39–4.77, P-value<0.01) odds
of transmitting in utero. Women who had BED<0.8/CD4<200
were most likely to transmit in utero (aOR 3.73, 95% CI 1.27–
10.96, P¼ 0.02). BED and CD4 cell count were not predictive of
intra-partum infections.
Conclusions These data provide evidence that in utero transmission of HIV might
be higher among women who seroconvert during pregnancy.
Keywords BED, CD4, in utero, intra-partum, seroconversion, HIV
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Introduction
Primary infection1–8 is characterized by elevated viral
load9–18 which is a strong risk factor for sexual trans-
mission15 and all modes of mother-to-child transmis-
sion (MTCT) of HIV.19 We recently reported data from
the ZVITAMBO vitamin A trial demonstrating that
breastfeeding-associated HIV transmission was
2.9–4.6 times higher among mothers who serocon-
verted post-natally compared with mothers who
were already infected at delivery. Among 17 mothers
who were seroconverted during delivery (i.e. their
blood tested negative by HIV ELISA but positive by
HIV RNA PCR), 75% of their infants died or became
infected by 9 months post-partum.20 Thus within
ZVITAMBO, maternal seroconversion during the
intra-partum and post-natal periods was associated
with high risk of MTCT.
Reports have been inconsistent, however, regarding
whether maternal seroconversion during pregnancy
increases in utero MTCT.21–24 It is important to under-
stand whether primary HIV infection during preg-
nancy increases transmission risk: firstly, because
the risk of HIV acquisition may be higher during
pregnancy than non-pregnancy;25–27 secondly, to
strengthen HIV prevention messages targeting
reproductive-aged couples; and lastly, to determine
whether repeat HIV testing and screening of antenatal
women is warranted.
Within the ZVITAMBO trial we previously noted
that women testing HIV-negative were younger and
were more educated than those testing HIV-positive.
Moreover, we noted that among HIV-positive women,
those who transmitted in utero were younger, were
more educated and also had a higher CD4 cell count
than those who transmitted intra-partum or
post-natally.28 We hypothesized that the group that
transmitted in utero may have included a large
number of women who seroconverted during
pregnancy.
We used the BED capture enzyme-immunoassay
(henceforth BED), a technically simple and relatively
cheap assay, to measure plasma concentration of
HIV-specific antibodies (IgG) that increase with
time following primary infection. Individuals present-
ing with ‘low’ (<0.8) normalized optical density
(ODn) values on BED are likely to have been in-
fected within the past half year.29 Although the
BED assay was designed to estimate the proportion
of recently acquired HIV at the population level, in
this analysis we used BED in combination with CD4
cell count as a proxy for acute infection to distin-
guish HIV-positive women who were likely to have
acquired HIV during pregnancy from chronically
infected women. We then compared in utero and
intra-partum transmission rates between these
groups to estimate the risk of in utero and intra-
partum MTCT associated with primary HIV infection
during pregnancy.
Methods
The ZVITAMBO project protocol and primary out-
comes have been reported elsewhere.28–31 In brief,
14 110 mother–infant dyads were enrolled within
96 h of delivery between November 1997 and
January 2000. Mother–infant pairs were eligible if
both were free of acutely life-threatening conditions,
the baby was a singleton with birth weight 51500 g
and the mother planned to stay in Harare after deliv-
ery. Written informed consent was obtained.
Baseline data were collected by interview, medical
record transcription or direct measurement. Gesta-
tional age was estimated using the Capurro
method.32 Infant birthweight and maternal mid-upper
arm circumference (MUAC) were measured using
published methods.33 Mother–infant pairs were fol-
lowed up at 6 weeks, 3 months and then every 3
months to 12 or 24 months. The trial preceded avail-
ability of HIV testing and anti-retroviral prophylaxis
for antenatal women in Harare public sector facilities.
Laboratory procedures
At baseline, all mothers were tested for HIV using an
algorithm that included two parallel enzyme-linked
immunosorbent assays [HIV 1.0.2 ICE (Murex
Diagnostics); GeneScreen HIV 1/2 (Sanofi
Diagnostics Pasteur)] and Western blot [HIV Blot
2.2; (Genelabs Diagnostics)] where results were dis-
cordant. Haemoglobin (Hb) was measured for women
enrolled from 1 October 1998 onwards (60% of the
total sample) (HemoCue, Mission Viejo, CA, USA).
For HIV-positive women, CD4 cells were enumerated
(FACsCount; Becton Dickinson) and plasma assayed
by the Calypte HIV-1 BED Incidence EIA (BED-CEIA),
(cat. No. 98003; Calypte Biomedical Corporation, Lake
Oswego, OR, USA).
From infants born to HIV-positive mothers, cell pel-
lets (Roche Diagnostics Systems, Alameda, CA, USA)
and plasma were prepared from whole blood collected
at baseline and follow-up visits and stored at –708C.
Following all patient contact, the last available sample
from each infant was tested [pellet by Roche
Amplicor version 1.5 qualitative DNA PCR assay
(Roche Diagnostic Systems) for samples collected
prior to 18 months; serum by GeneScreen ELISA for
samples collected after 18 months]. If this sample was
negative, the child was classified as HIV-negative; if
it was positive, then earlier samples were tested to
determine timing of infection.
The ZVITAMBO trial was approved by the Medical
Research Council of Zimbabwe (MRC-Z), the
Medicines Control Authority of Zimbabwe, the
Johns Hopkins Bloomberg School of Public Health
Committee on Human Research (CHR) and the
Montreal General Hospital Ethics Committee
(MGHEC). BED analysis of archived specimens was
approved by MRC-Z, CHR, MGHEC and CDC
Program Ethics Review Board, whereas the
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University of the Witwatersrand Human Research
Ethics Committee (Medical) approved the current
research.
Statistical analysis
Infant HIV infection groups
HIV-exposed children were classified into one of
three HIV status groups: (i) in utero infected (infant-
tested PCR-positive at baseline), (ii) intra-partum in-
fected (infant-tested PCR-negative at baseline and
PCR-positive at 6 weeks) and (iii) not infected at
6 weeks (infant-tested PCR-negative at 6 weeks
or later).34
Maternal likelihood of recent seroconversion
We used the BED assay together with CD4 cell count
to categorize HIV-1-positive women according to their
likelihood of having acquired HIV during pregnancy.
Recently-infected individuals are likely to present with
low BED values (ODn<0.8)29 and relatively high CD4
cell counts, Figure 1.35 People with advanced stage
HIV-1 may also present with low BED readings,36
but they usually have low CD4 cell counts. On fitting
multinomial logistic regression models using three
outcome levels, it was found that there was a signifi-
cant interaction term (P-value¼ 0.03) between BED
and CD4 cell count as continuous variables. We cate-
gorized women according to their BED and CD4 cell
count values informed by this significant interaction
term and the natural history of HIV infection as illu-
strated in Figure 1.35
Women were classified into one of six discrete
groups according to their BED ODn and CD4 cell
count interpreted as the following HIV duration and
severity:
(i) BED5 0.8/CD45 350 cells/ml (characteristic of
chronic asymptomatic infection).
(ii) BED5 0.8/CD4 200–349 (characteristic of
chronic intermediate stage infection).
(iii) BED5 0.80/CD4<200 (characteristic of
chronic end-stage infection).
(iv) BED<0.8/CD45 350 (characteristic of recent
infection).
(v) BED<0.8/CD4 200–349 (characteristic of the
short interval of primary infection when CD4
cell count falls precipitously as illustrated in
Figure 1).
(vi) BED<0.8/CD4<200 (characteristic of very
severe end-stage infection where BED declines
due to depressed antibody production), Table 3.
The primary comparison was between group 1 and
each of groups 4 and 5. We performed sensitivity ana-
lysis by combining groups (1 and 2) and (1, 2 and 3),
and comparing these new groups with combined
group (4 and 5). We assessed the effect of missing
CD4 cell count data by comparing models with
Figure 1 Relationship among peripheral blood CD4þ T-cell count, plasma viremia and clinical disease progression. During
the early period after primary infection, there is widespread dissemination of virus and a sharp decrease in the number of
CD4 T cells in peripheral blood. An immune response to HIV ensues, with a decrease in detectable viremia followed by a
prolonged period of clinical latency. The CD4 T-cell count continues to decrease during the following years, until it reaches a
critical level below which there is a substantial risk of opportunistic diseases. (From Pantaleo G, Graziosi C, Fauci AS. The
immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327–35, with permission.)
IN UTERO AND INTRA-PARTUM HIV RISK 3
 at U
n
iv
ersity
 o
f W
itw
atersran
d
 o
n
 F
eb
ru
ary
 1
6
, 2
0
1
2
h
ttp
://ije.o
x
fo
rd
jo
u
rn
als.o
rg
/
D
o
w
n
lo
ad
ed
 fro
m
 
complete data with models where CD4 was
imputed.37 Maternal age, MUAC, Hb and plasma
viral load were used to estimate for missing CD4
cell counts.
The data were analysed in STATA release 10
(STATACORP version 10; College Station, TX).
Baseline characteristics were compared across infant
infection status categories using ANOVA for continu-
ous variables, except in the case of extreme
non-normal variables where a Kruskal–Wallis test
was used. Chi-squared tests were used for categorical
variables. To compare the risk of in utero and
intra-partum infection between recent infection and
chronic infection, we fitted both unadjusted and ad-
justed multinomial logistic regression models, using
three outcome levels namely in utero, intra-partum
or PCR-negative at 6 weeks. We adjusted for maternal
factors: Hb level, MUAC, age, education, mode of
delivery and duration from rupture of membranes to
delivery. We also adjusted for the infant’s gender, ges-
tational age and birthweight. We did not adjust for
maternal viral load since the main question of interest
was whether in utero or intra-partum transmission
was associated with incident infection during preg-
nancy. Estimates were reported with 95% CIs.
Results
A total of 4495 women enrolled in the ZVITAMBO
trial tested HIV positive at baseline; 382 and 508 of
their neonates were infected during the in utero and
intra-partum periods, respectively, 2883 tested
PCR-negative at 6 weeks and the remainder (722)
had an undefined or missing HIV status. As previ-
ously reported, mothers who transmitted HIV during
the in utero period were younger and had better edu-
cation than mothers who transmitted intra-partum or
who did not transmit by 6 weeks, and mothers trans-
mitting in utero had higher CD4 cell counts than
mothers who transmitted intra-partum. A new find-
ing not previously published, is that the in utero group
also had higher plasma viral load (despite having
higher CD4) compared with the intra-partum group,
Table 1. Infants not included in the analysis due to
missing timing of HIV infection had a lower mean
birthweight (2.83 vs 2.93 kg), were born slightly ear-
lier (gestational age 38.9 vs 39.2 weeks), their
mothers had lower median CD4 cell count (382 vs
403 cells/ml) and their mothers’ plasma viral load
was higher (log10 4.20 vs 3.99 copies/ml) compared
with infants included in the analysis.
Maternal baseline factors and BED
assay results
Of the 4495 HIV-positive mothers, 4466 had a base-
line BED reading and 509 (11%) of these had a low
BED (<0.8 ODn) reading. Compared with mothers
with BED values 50.8, mothers with a low BED
were younger, had better education and higher CD4
cell counts (Table 2). Viral load values were
more widely distributed among women with low
BED readings than in those with high BED readings
(IQR¼ 3.26–4.71 compared with 3.39–4.57). Similarly,
the proportion of women with both undetectable viral
load (<2.6 log10) and very high viral load (44.6 log10)
was greater among women with low BED readings.
Risk of in utero and intra-partum
transmission according to BED and CD4
cell count
Among chronically infected women (BED5 0.8/
CD45 350), 156 (9.1%) of their neonates tested
PCR positive at birth compared with 34 (13.4 %)
among women described as recently infected
(BED<0.8/CD45 350), Table 3. Among women
with BED5 0.8/CD45 200 (a more liberal definition
of chronic infection), 225 (9.1%) neonates tested PCR
positive at birth, and this percentage hardly changed
(275 or 9.4%) when BED5 0.8 readings irrespective
of CD4 count were considered. Among women with
BED<0.8/CD45 200, a broader definition of recent
infections, 48 (14.9%) neonates tested PCR positive
at birth. In the intra-partum groups, 180 (10.5%)
and 19 (7.5%) were classified in the chronic and re-
cently infected groups, respectively, and these per-
centages hardly changed when different definitions
of chronic and recent infections were used.
In unadjusted models, a low BED (<0.8) reading
was a risk factor for in utero transmission (OR¼
1.68, 95% CI 1.26–2.25) and a protective factor for
intra-partum transmission (OR¼ 0.63, 95% CI 0.44–
0.90). The odds of in utero infection ranged from
1.37 (95% CI 0.90–2.08) to 2.64 (95% CI 1.37–5.06)
times higher when comparing women with
BED<0.8/CD45 350 and BED<0.8/CD4 200–349 to
women with BED5 0.8/CD45 350 in adjusted multi-
nomial models, Table 4. In sensitivity analysis the
odds of in utero transmission were 1.54 (95% CI
1.08–2.20; P¼ 0.02) and 1.47 (95% CI 1.03–2.09;
P¼ 0.03) times higher when comparing a group with
BED<0.8/CD45 200 (4 and 5) with BED5 0.8/
CD45 200 (1 and 2) and BED5 0.8/all CD4 groups
(1, 2 and 3) in adjusted models respectively.
Based on multiple adjusted models, the odds of
intra-partum infection ranged from 12% (95% CI
ÿ127; 66%) to 23% (–28; 54%) lower in recently in-
fected women when compared with chronically in-
fected, although the variances of the estimates were
large. When the recently infected group (4 and 5) was
compared with the two definitions of chronically in-
fected groups (1 and 2; and 1, 2 and 3) in sensitivity
analysis, the odds were 0.69 (95% CI 0.43–1.07;
P¼ 0.10), and 0.60 (95% CI 0.38–0.93; P¼ 0.03),
respectively.
In sensitivity analysis models with imputed CD4 cell
count data, the aOR estimates for in utero infection
were 2.85 (95% CI 1.55–5.26, P<0.01) and 1.38
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(95% CI 0.95–2.00, P¼ 0.09) for BED<0.8/CD4 200–
349 and BED5 0.8/CD45 350, respectively, compared
with BED5 0.8/CD45 350. The estimates were 0.98
(0.41–2.32, P¼ 0.96) and 0.65 (0.41–1.04, P¼ 0.07) for
intra-partum infection comparing BED<0.8/CD4
200–349 and BED5 0.8/CD45 350 relative to
BED5 0.8/CD45 350.
Other factors associated with in utero and
intra-partum transmission
Other factors that were independently associated with
in utero infection in multiple multinomial logistic
models were: gender adjusted odds ratio (aOR) 1.56
times for females compared with males, birthweight
aOR 0.50, 50% lower odds for every kilogram increase
in birthweight, maternal age aOR 0.96, 4% lower odds
for a year increase in mother’s age, mode of delivery
aOR 0.54, 46% less odds for caesarean delivery com-
pared with vaginal deliveries and maternal Hb aOR
0.36, 64% lower odds for HBs 411mg/dl compared
with HBs <7mg/dl, Table 4. Gestational age aOR
0.92, 8% lower likelihood of intra-partum infection
for a week increase in gestational age, mother’s edu-
cation aOR 0.62, 38% less odds of infection comparing
Table 1 Baseline characteristics of infant–mother dyads in which HIV transmission occurred intra-uterine and
intra-partum and post-natal/did not get infecteda
Characteristics
Intra-uterine
(n¼ 382) n (%)
Intra-partum
(n¼ 508) n (%)
PCR negative at
6 weeks
(n¼ 2883) n (%)
Overall
P-valueb
Infant
Male sex 153 (40.2) 250 (49.2) 1473 (51.1) <0.001
Birth weight, g [ x(SD)] 2.79 (0.47) 2.88 (0.49) 2.96 (0.45) <0.001
Gestational age, weeks [ x(SD)] 39.0 (1.6) 38.9 (1.6) 39.2 (1.4) <0.001
Maternal
Age, years [ x(SD)] 24.8 (4.6) 26.3 (5.4) 25.7 (5.0) <0.001
Schooling, years
<8 12 (3.2) 38 (7.5) 142 (4.9)
8 to <12 170 (44.6) 245 (48.2) 1334 (46.3)
512 199 (52.2) 225 (44.3) 1402 (48.7) 0.016
Mode of delivery
Vaginal 351 (93.9) 465 (92.4) 2597 (90.6)
Caesarean section 23 (6.1) 38 (7.6) 270 (9.4) 0.062
Rupture of membranes to delivery (hours)
44 147 (39.8) 231 (47.4) 1052 (40.0) <0.001
MUAC, cm [ x(SD)] 25.6 (2.9) 25.4 (2.6) 25.8 (3.0) 0.001
Hb, g/dl [ x(SD)] 10.9 (2.2) 10.7 (2.0) 11.2 (1.9) <0.001
CD4 cell count, cells/100 ml
Median (IQR)c 400 (262–542) 322 (185–492) 418 (276–588) <0.001
<200 56/328 (17) 123/436 (28) 317/2521 (13)
200–349 83 (25) 115 (26) 628 (25)
5350 189 (58) 198 (45) 1576 (63) <0.001
Plasma viral load, log10 copies/ml
Median (IQR)c 4.58 (4.00–5.09) 4.37 (3.90–4.90) 3.95 (3.42–4.46) <0.001
<3.38d 35/376 (9.3) 57/493 (11.6) 840/2830 (29.7)
3.38–4.6 164 (43.6) 238 (48.3) 1463 (51.7)
44.6 177 (47.1) 198 (40.2) 527 (18.6) <0.001
Undetectable viral load 6/376 (1.6) 13/493 (2.6) 245/2830 (8.7) <0.001
aAll value are n (%) except where noted otherwise.
bChi-squared/ANOVA/Kruskal–Wallis test as appropriate.
cKruskal–Wallis test used.
d<3.38 is below lower quartile (Q1), and44.6 is above upper quartile (Q3).
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women with 512 years of education with women
with 0–7 years spent at school, mode of delivery
0.57, 43% lower odds for intra-partum infection for
babies delivered by caesarean section compared with
vaginal deliveries, prolonged duration of rupture of
membranes aOR 1.49 times higher odds of infection
intra-partum for duration of rupture to delivery of
54 h compared with periods of <4h and maternal
HBs aOR 0.39, 61% lower odds for HBs 411mg/dl
compared with <7 g/dl.
Discussion
Maternal acute HIV infection during the post-partum
period has been associated with increased risk
of MTCT in breastfeeding populations.11,20,38,39
Although 50–90% of individuals with primary HIV in-
fections do present with symptomatic seroconversion
illnesses, their symptoms are usually non-specific and
are similar to many common febrile illnesses, with
pregnancy further clouding the issue.40–42 Most
Table 2 Baseline characteristics of HIV-positive post-partum women according to BED
assay resultsa
Characteristic
BED<0.8 ‘low’
(n¼ 422)b n (%)
BED5 0.8 ‘high’
(n¼ 3350)b n (%) P-valuec
Maternal
Age, years [ x(SD)] 23.9 (4.9) 25.9 (5.0) 0.001
Schooling, years
<8 13 (3.1) 179 (5.4)
8 to <12 175 (41.6) 1574 (47.0)
512 233 (55.3) 1593 (47.6) 0.005
MUACd, cm [ x(SD)] 25.6 (2.6) 25.8 (2.9) 0.175
Hb, g/dl [ x(SD)] 11.3 (2.1) 11.1 (1.93) 0.070
CD4 cell count, cells/100 ml
<200 25/346 (7.2) 469/2937 (16.0)
200–349 67 (19.4) 759 (25.8)
5350 254 (73) 1709 (58.2) <0.001
Plasma viral load, log10 copies/ml
<3.38 116/414 (28) 816/3285 (24.8)
3.38–4.6 178 (43.0) 1687 (51.3)
44.6 120 (29.0) 782 (23.8) 0.005
Percentage undetectable RNA 57/414 (13.8) 207/3285 (6.3) <0.001
aAll values are n (%) except where noted otherwise.
bMissing values if numbers do not add-up to this total.
cChi-squared tests for categorical comparisons and t-test for continuous variables.
dMid-upper arm circumference.
Table 3 In utero and intra-partum transmission according to baseline maternal BED ODn and CD4 cell count
Maternal baseline BED ODn and CD4 cell count groups Transmission n (%)
Group
BED ODn and CD4 count
(cells/ml) group
HIV duration and severity
interpretation In utero n¼ 382
Intra-partum
n¼ 508
1 BED5 0.8 and CD45 350 Chronic early stage 9.1 (156) 10.5 (180)
2 BED5 0.8 and CD4 200–349 Chronic intermediate stage 9.1 (69) 14.5 (110)
3 BED5 0.8 and CD4<200 Chronic end-stage 10.7 (50) 24.6 (115)
4 BED<0.8 and CD45 350 Recent early stage 13.4 (34) 7.5 (19)
5 BED<0.8 and CD4 200–349 Recent intermediate stage 20.9 (14) 7.5 (5)
6 BED<0.8 and CD4<200 Severe end-stagea 20.0 (5) 28.0 (7)
aDuring severe end-stage HIV, antibody production declines; this category of low BED and low CD4 probably reflects this
disease stage.
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Table 4 Risk of in utero and intra-partum infection for women with low BED and high CD4 count at delivery
Risk Factors (levels)
Intrauterine transmission Intrapartum transmission
Univariable
Multivariable
Univariable
Multivariable
OR (95% CI) OR (95% CI) P-value OR (95% CI) OR (95% CI) P-value
Infant factors
Sex
Males 1 1 1
Females 1.56 (1.25–1.94) 1.56 (1.21–2.00) 0.01 1.08 (0.89–1.30)
Gestational age, weeks 0.91 (0.85–0.98) 0.88 (0.83–0.94) 0.92 (0.84–0.99) 0.03
Birth weight, g 0.44 (0.35–0.56) 0.50 (0.33–0.61) <0.01 0.66 (0.54–0.82)
Maternal factors
Age, years 0.96 (0.94–0.98) 0.96 (0.93–0.99) <0.01 1.02 (1.01–1.04)
Education, years
0–7 1 1 1
8–11 1.51 (0.82–2.78) 0.69 (0.47–1.01) 0.66 (0.42–1.04) 0.80
512 1.68 (0.91–3.08) 0.60 (0.41–0.88) 0.62 (0.39–0.99) 0.04
MUAC, cm 0.98 (0.94–1.02) 0.95 (0.92–0.99)
Hb, g/dl
<7 1 1 1 1
7–10 0.58 (0.29–1.18) 0.53 (0.23–1.26) 0.15 0.60 (0.32–1.15) 0.59 (0.26–1.32) 0.20
511 0.40 (0.20–0.80) 0.36 (0.15–0.84) 0.02 0.40 (0.21–0.76) 0.39 (0.17–0.87) 0.02
Mode of delivery
Vaginal 1 1 1 1
Caesarean section 0.63 (0.41–0.98) 0.54 (0.30–0.97) 0.04 0.79 (0.55–1.12) 0.57 (0.36–0.92) 0.02
Prolonged rupture of membrane (h)
<4 1 1 1
54 1.08 (0.87–1.35) 1.47 (1.21–1.79) 1.49 (1.20–1.86) <0.01
BED/CD4 interaction terms
BEDCD4 (CD4 continuous) 0.87 (0.75–1.01) 0.93 (0.77–1.11)
BEDCD4 both continuous 1.05 (1.01–1.10) 0.99 (0.95–1.03)
BED
50.8 (long-term) 1 1
<0.8 (recent) 1.68 (1.26–2.25) 0.63 (0.44–0.90)
CD4
<200 (end-stage) 1 1
200–349 (intermediate stage) 0.76 (0.52–1.09) 0.47 (0.35–0.63)
5350 (early stage) 0.69 (0.50–0.95) 0.33 (0.25–0.42)
Group BED/CD4
1. BED5 0.8 and CD45 350 1 1 1 1
2. BED5 0.8 and CD4 200–349 1.45 (0.78–1.41) 1.10 (0.80–1.51) 0.56 1.45 (1.12–1.87) 1.45 (1.11–1.90) 0.01
3. BED5 0.8 and CD4<200 1.46 (1.04–2.06) 1.61 (1.12–2.32) 0.01 2.91 (2.23–3.79) 2.07 (2.03–3.60) <0.01
4. BED<0.8 and CD45 350 1.49 (1.00–2.22) 1.37 (0.90–2.08) 0.14 0.72 (0.44–1.19) 0.77 (0.46–1.28) 0.31
5. BED<0.8 and CD4 200–349 2.57 (1.39–4.77) 2.64 (1.37–5.06) <0.01 0.80 (0.31–2.03) 0.88 (0.34–2.27) 0.80
6. BED<0.8 and CD4<200 3.39 (1.19–9.64) 3.73 (1.27–10.96) 0.02 4.12 (1.62–10.45) 2.71 (0.93–7.86) 0.07
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prevention of mother to child transmission (PMTCT)
programmes in developing countries provide a single
test sometime during the antenatal period. Mothers
who test positive are then likely to be enrolled into
PMTCT programmes. Major reductions have been re-
ported in intra-partum and breastfeeding transmis-
sion (the two MTCT modes contributing the biggest
portion of all MTCT) due to HIV prophylaxis and
feeding options.34,43 It is thus likely that in utero
transmission will contribute proportionately more to
total MTCT compared with other transmission
times.44,45 Women with low BED reading and a mod-
erate CD4 cell count were more likely to transmit to
their unborn children than women with high BED
and high CD4 cell count (aOR¼ 2.64, P<0.01),
although the effect for women with a low BED read-
ing and high CD4 cell count was smaller (aOR¼ 1.37,
P¼ 0.14). Reproductive-aged women should be edu-
cated about this higher risk of transmitting to their
unborn child associated with seroconversion during
pregnancy.17
We have previously reported a 2.90–4.60 times
increased risk of post-natal MTCT among breastfed
children if the mother seroconverted during this
period.20 This risk is much higher than the 1.37–
2.64 times risk reported here, suggesting that the
transmission risk associated with maternal primary
infection may be lower for placental than
breastfeeding-associated transmissions. This is further
supported by the fact that intra-partum and
post-natal transmissions individually contribute
more to total MTCT where anti-retroviral treatment
is not available.31,44
We acknowledge that our interpretation of HIV dur-
ation and severity for each BED/CD4 group is imper-
fect and may have resulted in misclassification,
especially among women with BED<0.8 and CD4
200–350, whose risk of in utero transmission was
higher than that of chronically infected women. We
judged that this combination of BED and CD4 cell
count values reflected the nadir in CD4 count that
occurs during the acute phase of HIV infection and
therefore classified these women as having been re-
cently infected. However, this BED/CD4 combination
may also reflect a period of advanced disease when
antibody production is depressed, but CD4 count has
not yet dropped below 200. If any women in this
BED<0.8/CD4 200<350 group were truly chronically
infected, our estimate of excess in utero transmission
risk due to maternal primary infection during preg-
nancy would have been biased towards the null if the
misclassified women had a lower risk compared with
the truly acutely infected women.
In our previous publication, the infant death or in-
fection rate among the 17 women whose blood
sample near delivery tested HIV ELISA negative but
HIV RNA PCR positive was 75%; clearly mothers who
deliver during HIV seroconversion (when HIV antibo-
dies remain undetectable and viral load is extremely
high) are at very high risk of peri-partum transmis-
sion.20 In this report, women likely to have acquired
HIV infection during pregnancy, based on their BED/
CD4 group, were not at increased risk of intra-partum
transmission compared with chronically infected
women. Indeed, our risk estimates of intra-partum
infection were consistently lower for women classified
as recently infected compared with chronically in-
fected women although all OR CIs overlapped 1
except in one comparison. This is probably because
all the women included in the current report tested
positive for HIV-antibodies at delivery, indicating they
had completed the brief ‘window period’ of the ELISA
assay (when HIV antibodies are undetectable but viral
load is very high) and were now in a much lower risk
period of early asymptomatic disease characterized by
high antibody, high CD4, low viral concentrations.
In sensitivity analysis models with imputed CD4 cell
count, adjusted estimates for in utero and intra-
partum infections were consistent with those
obtained with observed data, although they had smal-
ler CIs (i.e. smaller standard errors).
Similar to other studies, the risk for in utero
infection was inversely related with birthweight,
with smaller babies at increased risk of infec-
tion.19,34,39,44,46 It is not clear whether an infected
fetus fails to grow properly or fetal growth impair-
ment predisposes the unborn child to increased risk
of HIV infection.44,47–48 The proportion of infants with
low birthweight was 16% overall in this study, 24% of
those infected in in utero, 22% in intra-partum and
14% among infants who tested negative at 6 weeks.
Prematurity has been cited as a risk factor for infec-
tion because of immature immune systems, perme-
ability of neonatal mucosal barriers and low levels
of maternal antibodies which are normally transferred
in the latter half of pregnancy.34,49,50
There was a 43–46% lower risk of infection among
babies born by caesarean section than those delivered
vaginally in both the in utero and intra-partum
groups.1 Prolonged rupture of membranes before de-
livery resulted in a 50% excess risk in intra-partum
infection as reported elsewhere.34,39,44,48 Among vagi-
nal deliveries in our study, 37% had rupture-of-
membranes-to-delivery durations of 44 h, whereas
among emergency caesarean sections, 72% had pro-
longed rupture of membranes and only 17% among
elective caesarean sections. Babies are exposed to
cervico-vaginal secretions during prolonged rupture
of membranes thus increasing the likelihood of infec-
tion.51 Long duration of ruptured membranes before
delivery and low CD4 cell count high viral load have
been reported to increase risk of HIV transmis-
sion.39,52 It is unlikely that elective caesarean sections
will ever become the choice of delivery in the most
affected HIV regions because of the huge challenges
in cost, personnel and equipment. Other efforts to
reduce the risk of infection such as reducing viral
load have to thus be scaled up in these areas.
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Research on optimal and easy-to-apply anti-retroviral
treatment protocols should continue.
In conclusion, our findings indicate that the risk of
in utero HIV transmission is likely to be greater among
women who have their primary HIV infection during
pregnancy compared with women who were infected
prior to conception. Our estimates of this excess risk
ranged from 1.37 (95% CI 0.90–2.08) to 2.64 (95% CI
1.37–5.06), which are lower than the excess risk of
transmission during breastfeeding among women
who seroconvert during the breastfeeding period.
This suggests that the placenta may be a more effect-
ive barrier to the high viral load of primary infection
than the mammary gland.
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MODELLING BED CAPTURE ENZYME IMMUNOASSAY (CIEA) IN 
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Abstract 
The aim of this paper is to describe the functional form of the relationship between 
the probability of being recently infected with HIV (as opposed to having been 
infected for a long time) and BED optical density levels, and to examine how this 
relationship is modified by other markers such as viral load, haemoglobin and mid-
upper arm circumference.   
Participants 
Initially HIV negative women with known seroconversion dates and women who 
tested ELISA HIV-1 positive at the time of recruitment had BED normalized Optical 
Density (ODn), ribo-nucleic acid viral load, haemoglobin, and mid-upper arm 
circumference measured.  
Methods 
Fractional Polynomial (FP), linear and categorical independent factors were used to 
assess the functional form of the BED ODn on the probability of being recently 
infected. The influence of viral load, haemoglobin and maternal mid-upper arm 
circumference were investigated in multivariable logistic regression models.  
Results 
Fractional Polynomial regression models described the functional form of the 
relationship between the probability of being recently HIV-infected and BED ODn 
better than either linear or categorical specifications of BED ODn. Use of a linear 
BED ODn term over-estimated the likelihood of recent infection for lower values of 
BED ODn, while categorical models had unrealistic jumps in the probability of recent 
infection.  
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Conclusions 
Viral load, haemoglobin and mid-upper arm circumference did not change the 
relationship between probability of being recently infected and BED ODn levels. 
 
Key Words: Fractional polynomial, BED assay, HIV recent infection 
Word count: Abstract 227 
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Introduction 
A number of laboratory assays have been proposed to distinguish between recent 
HIV-1 infections and long term HIV-1 infections [15, 30, 43, 72]. The assays are 
based on qualitative and/or quantitative changes in antibody levels before or after 
HIV-1 sero-conversion and involve the duration of a transient state related to 
changing virologic or immunologic response in early HIV-1 infection. This can be 
achieved through the detection of the virus before antibody sero-conversion (HIV-1 
RNA or HIV-1 p24 assays) or through characterizing the initial antibody response that 
differs from that of established infection (anti-body titer, proportion specificity, 
isotpye or avidity) [15, 73]. HIV infected individuals are said to be recently infected if 
HIV virus is detectable in their blood and no detectable antibodies to the virus or if 
they are below certain cut-off levels on given antibody markers.   
 
The BED Capture Enzyme Immunoassay (CEIA), hereafter referred to as BED, is an 
HIV-1 incidence assay that quantitatively measures the proportion of IgG antibodies 
associated with HIV-1; this proportion rises over the first year of infection [72]. IgG 
is a protein whose concentration in the blood reflects the cumulative exposure of the 
immune system to antigens such as bacterial or viral infections. The level of IgG used 
to classify individuals as recently infected or not was determined by modeling the 
kinetics of individual normalized optical density values (ODn) over time. The within 
subject profiles were found to be non-linear over time, with ODn levels rising before 
leveling off after 153 to 187 days hence the modeling of sero-conversion time was 
carried out using a linear mixed effects model of the square root transformed ODn 
level on log-time, with random effects to account for the correlation of responses 
within subjects. Survival type models were also investigated [52, 72, 74] . Estimates 
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of HIV incidence based on BED are sensitive to individual biological factors such as 
HIV-1 sub-type and population level factors such as HIV-1 prevalence [56, 75].   
 
A number of measures are used to assess the health status of HIV-1 infected 
individuals. These include serological markers such as RNA viral load, CD4 cell 
count and haemoglobin, and measures of general nutritional status, such as mid-upper 
arm circumference (MUAC). These measures are likely to differ between recently 
infected individuals and those with long established infections [76-79]. Recently 
infected people are likely to be relatively healthy and thus should have relatively high 
CD4 cell counts, high haemoglobin levels, and normal MUAC, but high HIV-viral 
loads until after optimal concentrations of HIV-specific antibodies are produced.  
Such recently infected people would be expected to have low BED ODn. In contrast, 
long term infected individuals in the chronic pre-AIDS stage of HIV-1 infection have  
lower CD4 cell count and haemoglobin concentration, may show signs of wasting 
(thus low MUAC), but may have lower viral load and should have  high BED ODn 
values. 
 
Unadjusted estimates of HIV-1 incidence based on BED have been reported to be 
higher than estimates found prospectively from cohort studies [52, 72, 80]. People 
testing “false-recent” by the BED assay may include individuals in whom the ODn 
assay values rise slowly in the first year of infection and never reach the cut-off that 
discriminate between new infections and long-term infections, as well as individuals 
with AIDS in whom antibody production has declined, yielding low ODn values.  
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The BED assay is used cross sectionally, thus it is important to model the probability 
of being recently infected as a function of the assay and to investigate how other 
markers affect this relationship. In this paper the probability of being newly infected 
is modeled among women enrolled in the Zimbabwe Vitamin A for Mother and 
Babies Project (ZVITAMBO).. Women and their new born babies were recruited into 
the study within 96 hours of parturition and followed up to 12 months postpartum [52, 
64, 81]. Women were tested for HIV at baseline and those testing negative were 
retested at 12 months to identify women who seroconverted during the postpartum 
year.   The objective of the paper is to examine the form of the relationship between 
the probability of having acquired HIV during the 12 month postpartum period and 
BED ODn levels and the effect of baseline viral load,  haemoglobin and MUAC on 
this relationship. Understanding the properties of the BED assay in identifying new 
HIV infections, and how this is related to other markers would provide insights into 
how the assay works. This can be used in defining new algorithms that combine these 
serological markers that better discriminate new from old HIV infections. The 
discriminating ability of the validated ODn cut off of 0.8 was assessed using 
fractional polynomial regression models in two groups of subjects.  
 
Methods  
The data used in this paper came from the ZVITAMBO project in which 14110 
women were recruited between November 1997 and January 2000 in Harare 
Zimbabwe [52, 64]. Written informed consent was obtained.  
 
At baseline, all mothers were tested for HIV-1 using an algorithm that included two 
parallel enzyme-linked immune-sorbent assays (HIV 1.0.2 ICE [Murex Diagnostics]; 
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GeneScreen HIV 1/2 [Sanofi Diagnostics Pasteur]) and Western blot (HIV Blot 2.2; 
[Genelabs Diagnostics]) when results were discordant.   Haemoglobin (HB) was 
measured for women enrolled from Oct 1, 1998 onwards (HemoCue, Mission Viejo, 
CA). For HIV-positive women, CD4 cells were enumerated (FACsCount; Becton 
Dickinson) and plasma assayed by the Calypte HIV-1 BED Incidence EIA (BED-
CEIA), (cat. No. 98003; Calypte Biomedical Corporation, Lake Oswego. OR). For 
baseline HIV-1 positive women and women who seroconverted between baseline and 
12 months, stored sera were analyzed by  the BED assay.  Normalized Optical 
Density (ODn) of less than 0.8 or greater than 1.2 were returned as the final 
readings.If ODn values were between 0.8 and 1.2 the samples were retested once and 
if the value was above 1.2 then that reading was taken as the final value, otherwise the 
sample was run in triplicate.  The median value for these three readings was then 
considered as the final reading. Serum RNA concentration (viral load) was quantified 
using the Roche Amplicor HIV-1 monitor test (version 1.5, Roche Diagnostics, 
Alameda, CA, USA). Viral load values for undetectable samples were set to the assay 
detection limit (400 copies/µL) in analyses where viral load was treated as a 
continuous variable. Viral load values were log10 transformed. CD4 cell testing was 
done on the first positive sample for seroconverting women.  
 
For participants to be included in this analysis they had to have complete data on viral 
load, haemoglobin and MUAC in addition to BED ODn readings. The first analysis 
set of women used in the analysis consisted of women at 12 months of follow-up who 
were known to be HIV infected at baseline and had complete data (n=1120) and 
women whose sero-conversion time was known to be within three months of the last 
negative and the first positive test (n=52). This analysis set defined as the restricted 
 47
analysis set, although small, has the advantage that subjects are clearly either long-
term infected (n=1120) or recently infected (n=52). A second, larger analysis set of 
women was also considered, namely women who tested HIV-1 positive at baseline 
(n=1565) as well as women who seroconverted postnatally regardless of the exact 
date of seroconversion (n=98). The advantage of this larger group defined as the full 
analysis set, in addition to the larger sample size, is that it is more representative of 
the actual population that would be encountered in a cross-sectional survey. The 
disadvantage is that there is a risk that some women would be misclassified, since 
some of the women who tested positive at baseline may have in fact been infected 
within the previous 6 months, which is the approximate window period of the BED 
assay. 
 
Models: Functional form of BED ODn for recent infection  
The logit of the binary outcome recent/long term infection based on observed follow-
up data was used as the outcome variable.  In order to provide a comparison for 
fractional polynomial models, conventional simple linear logistic regression models 
were fitted first:   
݈݋݃݅ݐሺ݌௜ሻ ൌ ߚ଴ ൅ ߚଵܱ݀݊ 
Categorized BED ODn values with r-1 dummy variables on the logit of infection were 
then considered next 
݈݋݃݅ݐሺ݌௜ሻ ൌ ߚ଴ ൅ ߚଵܱܦ݊ଵ ൅ ߚଶܱܦ݊ଶ ൅	…൅ ߚ௥ିଵܱܦ݊௥ିଵ 
The categorization included the manufacturer’s recommended 0.8 cut-off, as well as a 
grouping with cutoffs (min to 0.2), (>0.2 to 0.4), (>0.4 to 0.6), (> 0.6 to 0.8), (>0.8 to 
1.0), (>1.0 to 2.0), (>2.0 to 3.0) and (> 3.0 to max), (Tables 3 and 4). Thirdly, to 
investigate non-linearity in the relationship between the logit of infection and BED 
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ODn, fractional polynomials were used [67, 82]. The general form of the FP model is 
given by  
ߟ௜ሺܺ; ࢼ; ࢖ሻ ൌ 	෍ߚ௝݃௝ሺܺሻ
ௗ
௝ୀ଴
 
where for j = 0 to d where d is the number of the independent variables fitted in the 
model,  gj(X) is Xpj for pj ≠ pj-1 and gj-1(X) is Xpln(X) for pj = pj-1 and Xp denote the 
Box Tidwell transformation defined as Xp if pj ≠ pj-1 and ln(X) if pj = 0. The 
coefficients and powers of the model are contained in the vectors β = (β1, …,βd) and p 
= (p1, …,pd) such that p1 < … < pd respectively. The power list which is restricted to a 
pre-determined set of integers and non-integers: (-2, -1,-0.5,0,1,0.5,1,2,3 ) includes 
the reciprocal, logarithm, square root, square and repeated-powers transformations 
[67]. η is an appropriate link function, and in this paper the logit link is used.   The 
first-degree FP model with the smallest deviance (defined as minus twice the log 
likelihood) was selected as a basis for comparison with higher degree FP models if it 
was better than a null model. Among all second-degree FP models, the best second-
degree FP was selected based on the smallest deviance, and only when there was a 
statistically significant difference in deviance between the best first degree and the 
best second-degree FP would the second-degree model be selected as a better model. 
Third-degree FP models were considered only when there was an improvement in the 
first or second degree FPs. We used the likelihood ratio test and the Akaike 
Information Criterion (AIC) to determine the best model among linear, categorical 
and fractional polynomial models [70] . We plotted the probability of being recently 
infected versus BED ODn values for linear, categorical and fractional polynomials 
models for a graphical impression of fitted models. All models were fitted using 
STATA (STATA Version 10; College Station TX).  
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To assess the effect of other markers, univariable fractional polynomials were fitted 
first for all variables (viral load, Haemoglobin and MUAC) following the same 
procedures as described for BED ODn models i.e. fit first-degree, second-degree and 
third-degree models. Factors with p-values of 0.20 or less in unvariable models were 
considered for entry into the multivariable FP model. The final multivariable FP 
model had factors which were significant at the 5% significance level but including 
BED. The influence of other disease markers for linear and categorical models were 
assessed in a similar way, starting by univariable models and building multivariable 
models, assessing significance of factors using likelihood ratio tests.  
   
The full analysis set was used to illustrate FP model building (Table 1), in which 
univariable and multivariable linear, categorical and FP models were compared. The 
main comparisons and results are however shown for both analysis sets.   
 
The Medical Research Council of Zimbabwe (MRC-Z), the Medicines Control 
Authority of Zimbabwe, the Johns Hopkins Bloomberg School of Public Health 
Committee on Human Research (CHR), and the Montreal General Hospital Ethics 
Committee (MGHEC) approved the ZVITAMBO trial. BED analysis of archived 
specimens was approved by MRC-Z, CHR, MGHEC and CDC Program Ethics 
Review Board, and the University of the Witwatersrand Human Research Ethics 
Committee (Medical) approved the current research.  
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Results: 
One thousand six hundred and sixty three (1663) women; 1565 women who tested 
positive at time of recruitment and 98 women who sero-converted had complete data 
on BED ODn, viral load, haemoglobin and MUAC. One hundred and twenty four 
(124, 10%) of those who tested positive at baseline had undetectable viral load 
compared to 14 (14%) of sero-convertors (p-value = 0.03). When only women with 
well defined timing of HIV infection were used i.e. the restricted analysis set, 1120 
baseline positive and 52 sero-convertors had complete data.  When CD4 cell was 
considered only 16 sero-convertors had complete data, thus CD4 count was excluded 
from all models.   
 
Table 1 shows the best first-degree, second-degree and third-degree fractional 
polynomial models for BED, viral load, haemoglobin and mid-upper arm 
circumference respectively. The best FP model for BED ODn was a first-degree FP 
(0.5), although a second-degree FP was marginally significant, (likelihood ratio test p 
= 0.06). The second-degree FP model for BED ODn had powers (-2 ; 0.5) and it  was 
statistically significant in adjusted multivariable FPs. A second-degree FP model for 
viral load with powers (1 ; 1) was chosen as the best model among first, second and 
third-degree FP models. Haemoglobin had first-degree FP model with power (3) as 
the best model. All FP models fitted for mid-upper arm circumference were no better 
than the null model.  
 
The best second-degree FP models (-2 ; 0.5) and (1 ; 1)on BED ODn fitted the data 
better compared to the linear and categorical models using the restricted and the full 
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analysis set respectively, (Figures 1a and 1b). The linear model had a flatter gradient 
than both FP models for lower values of BED ODn, thus it failed to capture the rapid 
decline in the probability of being recently infected. The linear model overestimated 
infection probabilities for ODn values below 2. The categorical model did not capture 
the continuous rapid decline in risk for lower values of BED ODn. The step function 
had probability values (0.41, 0.14, 0.05, 0.04, 0.2 and 0.1) and (0.85, 0.39, 0.15, 0.09, 
0.03 and 0.004) for the full and restricted analysis set respectively for BED ODn 
groups (min to 0.2), (>0.2 to 0.4), (>0.4 to 0.6), (>0.6 to 0.8) (0.8 to 1.0) and (>1 to 
max).  Using the manufacturer’s 0.8 cut off gave two probability levels 0.29 and 0.02 
for BED ODn levels below and above 0.8 respectively using the full analysis set.    
 
In multivariable logit models based on the full analysis set, BED ODn, viral load, 
haemoglobin and mid-upper arm circumference fitted as linear independent factors 
were significant co-factors for recent infection, (Table 2).  In this model the 
univariable coefficient for BED ODn was -1.85 and it changed to -1.82 in an adjusted 
multivariable model. In multivariable models with all factors categorised, BED ODn 
and viral load were the only significant factors where the coefficient for BED ODn 
changed from 3.21 in a univariable model to 3.14 in a multivariable model. BED ODn 
with powers (-2 ; 0.5), viral load power (1), and haemoglobin power (1) in 
multivariable FP model were predictive of the probability of being recently infected.  
The coefficients for the FP model in univariable model for BED ODn were (0.0005 ; -
3.2007) and became (0.0007 ; -3.1158) in adjusted models. Viral load and 
haemoglobin were fitted as linear factors in multivariable FP models. Whereas mid-
upper arm circumference was statistically significant in linear models (p-value = 
0.04), it was not significant in multivariable FP models (p-value = 0.44). The 
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categorical model had the lowest AIC (406), although the FP model (AIC = 475) 
described the functional form of BED ODn and the probability of being recently 
infected better, (Figures 1a and 1b).   
 
The likelihood of being recently infected was high for low ODn values when the full 
analysis set was considered (Table 3 and Figure 1a).  Adjusting for viral load and 
haemoglobin did not change the odds of being classified as recently infected that 
much when BED ODn was assessed. Using ODn cut off of 0.8 in all FP models the 
odds was above 1 for BED values below 0.8 and was below 1 for values of BED 
above 0.8. When strict definitions for timing of infections were used, the separation 
between being recently infected and being a chronic case was very apparent in 
adjusted models, (Table 4 and Figure 1b). Adjusting for viral load and haemoglobin 
resulted in ‘noisy’ estimates of probability of being recently infected for lower levels 
of BED ODn values, (Figure 2).     
 
Discussion: 
To fully understand the utility of the BED assay for HIV-1 recent infection, it is 
necessary to evaluate how the assay relates to other markers such as viral load and 
hemoglobin, and MUAC. It is thus important to correctly describe the functional 
forms of these assays in HIV-1 infected individuals at different stages of infection. FP 
models were used to investigate the functional form of the BED ODn on the 
probability of being recently infected among HIV infected women. FP allows for the 
investigation of non-linear relationships, allows for correct adjustment of confounding 
and the modeling of complex interaction relationships [82-86]. The square root (on 
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ODn) and natural log (time) transformations were used to linearize the functional 
forms of the BED ODn over time using a panel of known HIV sero-convertors when 
estimating the window period of the BED assay [52, 72]. In this current study, FP 
fitted the probability of being recently infected against BED ODn levels best. Fitting 
BED ODn as an independent linear function resulted in over-estimation of the 
probability of being recently infected for low values of BED ODn, while the step 
functions resulted in unrealistic groupings for probability estimates, a tendency 
observed in other functional modeling studies [82, 84]. 
 
The functional forms for ODn for the restricted analysis set, powers (1 ; 1); logit(pi) = 
β0 + β1ODn + β2ODn*loge(ODn) was different from the full analysis set , powers (-2 ; 
0.5),logit(pi) = β0 + β1ODn-2 + β2ODn0.5 , (Figure 2). There was better discrimination 
by the BED assay between recently infected and long term infected individuals when 
analysis was restricted to participants with well defined timing of HIV infections. In 
the restricted analysis set, all women classified as long term infected had been 
infected for over one year, whereas in the full analysis data set some women could 
have been misclassified as having been infected for a long time when in fact they had 
been infected within the last six months. Adjusting for viral load and haemoglobin 
seemed to have little impact on this separation ability.  This has been shown as one of 
the major short-coming of the BED assay. When validated within known sero-
converting panels, the BED assay performed very well, but when it was applied to 
truly cross-sectional samples regardless of timing of infection, the assay incorrectly 
classified a considerable number of long term infected participants [34, 52, 87-89]. 
This problem is likely to be more profound in generalized HIV-1 epidemics 
characterized by large proportions of long term infected individuals. This 
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misclassified long term infected group inflates the numerator used in the calculation 
of HIV-1 incidence considerably, thus over estimating HIV incidence. In practice the 
problem of misclassifying the long term infected group might be lessened by 
removing AIDS patients [90]. It should however be noted that haemoblogin was 
measured at baseline only so its influence on the probability of being recently infected 
and BED may not have been properly captured. 
 
Viral load and hemoglobin were the only independent co-factors in the relationship 
between the likelihood of being recently infected and BED ODn. Viral load is 
expected to be elevated during the acute phase of infection before the host’s immune 
system is able to fully respond to the virus, as well as during the AIDS disease stage 
when the immune system cannot cope with high viral replication [91] . The role and 
relationship between these markers and iron levels is not clearly understood thus 
further research is needed. Adjusting for viral load and hemoglobin resulted in a lot of 
noise in the likelihood of being classified as recently infected for individuals with low 
BED ODn values. This could partly be a function of the relatively small number of 
recently infected participants.  The odds of being recently infected remained relatively 
stable in models adjusted for viral load and hemoglobin, suggesting that these two 
factors are independent co-factors for being recently infected. Because of the lower 
detection limits for viral load, we used the lower limit of detection (400 copies/µl) for 
all readings with undetectable levels. This might result in biased results because these 
readings are left censored.  
 
 The effect of CD4 cell count on the relationship between the probability of having 
been recently infected and BED ODn could not be explored in this study because only 
 55
16 CD4 count readings were available for recently infected participants. CD4 count 
levels are expected to drop during the acute phase of infection, but recover at lower 
levels of original values once antibodies to HIV-1 have been established. The nadir at 
which CD4 cell count levels rebound after sero-conversion is not well documented, 
although data from Uganda (subtype A and D) suggest that this nadir may be 
relatively high (above 400) with wide variations in the actual counts (personal 
communication Dr. Jonathan Levin, MRC/UVI Uganda Research Unit on AIDS). 
Current World Health Organization (WHO) antiretroviral treatment guidelines 
stipulate that treatment should commence at 350 CD4 cell counts or lower [92]. While 
low levels of CD4 count may be an indication of advanced disease, more research is 
need to understand CD4 level profiles around acute infection.          
 
Other alternatives to FP models to investigate non-linear relationships exist. These 
include Spline Regression which however easily become cumbersome as the number 
of factors to be fitted and/or the number of parameters to be estimated increase [93-
94].  FP models can however be affected by outliers and high influence values, thus 
resulting in wrong functional relationships between outcome and independent 
variables.  
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Table 1: Fractional polynomial model building for logit (recent infection)  
Model  1st degree (M1)  2nd – degree (M2) 3rd degree (M3)
  power  LL 
df = 2$ 
AIC Powers LL
df = 4$ 
AIC Chi‐2 Gain, p‐
value M2‐M1 
Powers LL
df = 6$ 
AIC Chi‐2 Gain, p‐
value M3‐M2% 
Odn  0.5  ‐246.9082  497.82 ‐2 0.5 ‐244.0339 494.07 5.75 (0.06)  ‐2 ‐2 0 ‐242.1001 492.20 3.87 (1.00)
Viral load  3  ‐357.3576  718.72 1 1 ‐352.9346 711.87 8.85 (< 0.01)  ‐2 ‐2 ‐2 ‐351.2212 710.44 3.43 (0.18)
Hemoglobin  3  ‐368.6369  741.25 0 0 ‐366.5401 739.08 4.17 (0.12)  3 3 3 ‐363.42 734.84 6.23 (0.18)
Muac  ‐2  ‐371.3739  746.75 3 3 ‐371.2262 748.45 0.30 (0.86)  3 3 3 ‐371.2119 750.42 0.32 (0.99)
This table uses full analysis set: All available data n = 1663 
Bold – Best model across each variable comparing powers 1, 2 and 3.  
Italics – These models are not any better than the NULL model 
% Except for MUAC where models are compared to M1 because M2 is not an improvement on M1 
$1-df for each estimated coefficient and 1-df for each power term 
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Table 2: Final multivariable models for logit recent HIV infection for women who seroconverted postnatally  
Variable  LL (df) β SE p‐value@
a). Assuming a linear function for continuous factors  ‐247.61 (4)
Odn  ‐1.82  0.22 < 0.01
Viral load  0.53  0.13 < 0.01
Haemoglobin  0.015  0.001 0.02
Mid‐upper arm circumference  0.08  0.04 0.04
 
b).  Categorical approach  ‐226.45 (3)
ODn 
>= 0.8 
< 0.8 
ref 
3.14 
 
0.26 
 
< 0.01 
Viral load 
< Q1 
Q1‐Q3 
> Q3 
ref 
‐0.05 
0.97 
 
0.29 
0.30 
 
0.85 
< 0.01 
Haemoglobin 
< 90 
90 – 110 
> 110 
ref 
Out 
Out 
Mid‐upper arm circumference 
< 23 
  23 – 25 
> 25 
 
Out 
Out 
 
c) Fractional polynomial model  ‐232.98 (8)
Odn‐2 
Odn0.5 
0.0007 
‐3.1158 
0.0004
0.3084 
0.04
< 0.01 
Viral load1  0.5589  0.1391 < 0.01
Haemoglobin1  0.0171  0.0067 0.01
Mid‐upper arm circumference1  Out 
This table uses the full analysis set: All available data, n = 1663 
@p-values are from likelihood ratio tests 
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Table 3: 2nd degree FP model for HIV incident infection on ODn, preserving the usual information from an analysis based on categories 
for all infected women regardless of timing of infection, (full analysis set).  
ODn*  Number  OR (Model based)
      Un‐ adjusted  Adjusted*
Range  Comparison 
point 
At risk  Infected Naïve proportion 
recently infected 
 (95% CI) 
Estimate 95% CI Estimate 95% CI
    0 – 0.2      0.15  85  46 0.541 (0.430 – 0.650) 5.18  3.96 – 6.84 5.00  3.81 – 6.58
    > 0.2 – 0.4      0.25  58  12 0.207 (0.112 – 0.334) 3.56 2.85 – 4.46 3.45 2.75 – 4.33
    > 0.4 – 0.6      0.45  55  9 0.164 (0.078 – 0.288) 2.05 1.80 – 2.33 2.01 1.76 – 2.30
    > 0.6 – 0.8      0.65  60  7 0.117 (0.048 – 0.226) 1.33 1.26 – 1.40 1.39 1.25 – 1.39
    > 0.8 – 1.0      0.90  39  2 0.051 (0.006 – 0.173) 0.84 0.81 – 0.87 0.84 0.82 – 0.87
    > 1.0 – 2.0      1.50  412  12 0.029 (0.015 – 0.050) 0.35 0.29 – 0.42 0.36 0.29 – 0.44
    > 2.0 – 3.0      2.50  510  8 0.016 (0.007 – 0.031) 0.11 0.07 – 0.17 0.12 0.08 – 0.18
    > 3.0      4.00  444  2 0.004 (0.001 – 0.016) 0.03 0.02 – 0.06 0.03 0.02 – 0.06
*logit(pi) = β0 + β1ODn-2 + β2ODn0.5+β3VL + β4HB, where coefficients are as in table-2. Model is adjusted for viral load, haemoglobin#. The reference point for all these comparisons is ODn = 0.8 
# Note that viral load and haemoglobin are fitted as linear functions.  
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Table 4: 2nd degree FP model for HIV incident infection on ODn, preserving the usual information from an analysis based on categories 
for women with well defined timing of HIV infection (restricted analysis set).  
ODn  Number  OR (Model based)
      Unadjusted   Adjusted*
Range  Comparison 
point 
At risk of being 
new infection 
Recent 
infections 
Naïve recent Incidence 
probability (95% CI) 
Estimate 95% CI  Estimate 95% CI
    0 – 0.2      0.15  40  34 0.85 (0.70 – 0.94) 57.52  (20.12 – 164.42) 62.21 20.85 – 185.61
    > 0.2 – 0.4      0.25  23  9 0.39 (0.20 – 0.61) 23.75  (9.09 – 62.05) 25.37 9.35 – 68.84
    > 0.4 – 0.6      0.45  23  2 0.09 (0.01 – 0.28) 5.87  (2.98 – 11.57) 6.12 3.02 – 12.37
    > 0.6 – 0.8      0.65  20  3 0.15 (0.03 – 0.37) 1.97  (1.44 – 2.69) 2.01 1.45 – 2.77
    > 0.8 – 1.0      0.90  33  1 0.030 (0.001 – 0.158) 0.67  (0.53 – 0.84) 0.66 0.53 – 0.84
    > 1.0 – 2.0      1.50  252  1 0.004 (0.0001 – 0.0219) 0.12  (0.02 – 0.69) 0.11 0.02 – 0.67
    > 2.0 – 3.0      2.50  352  0 0 (0 – 0.01) 0.04  (0.0003 – 4.28) 0.03 0.0002 – 4.15
    > 3.0      4.00  429  2 0.005 (0.0006 – 0.017) 0.07  (3.6 x 10‐6 – 1482.43) 0.05 1.83 x 10‐6 – 1443.73
* logit(pi) = β0 + β1ODn + β2ODn*loge(ODn)+β3VL, where β1 = -6.90, β2 = 3.34, β3 = -6.76 .  Model is adjusted for viral load#. The reference point for all these comparisons is ODn = 0.8, the manufacturer’s cut off for 
BED.  
# Note that viral load is fitted as a linear functions.  
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Figure 1a: Fitted estimated probability of recent incident HIV infection by BED ODn using full analysis set : blue dots –proportion recent 
infections in BED group (see Table 3), green - linear model, yellow - categorical step model, red - FP model (-2 ; 0.5).  
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Figure 1b: Fitted estimated probability of recent incident HIV infection by BED ODn using restricted analysis set : blue dots –proportion recent 
infections in BED group (see Table 4), green - linear model, yellow - categorical step model, red - FP model (1 ; 1).  
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Figure 2: Fitted estimated probability of recent incident HIV infection by BED ODn using: red line - restricted analysis set – blue line - full 
analysis set and green line - proportion recent.    
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SUMMARIZING DISCUSSION AND CONCLUSIONS  
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Chapter 5 Summarizing Discussion and Conclusions 
Simple laboratory assays that can be applied cross-sectionally hold great promise in 
getting timely and inexpensive estimates of HIV incidence urgently needed in the 
most affected areas of the world. Jassen et al.’s study in 1998 probably represents the 
turning point in the interest and possible resolution of availing timely usable assays 
that measure HIV incidence [30, 33, 46, 95-97]. A number of such assays have been 
proposed and among these assays the BED and 3A11 – LS are thought to be much 
more reliable for estimating HIV-1 incidence [16].  
 
Current cross-sectional assays used in incidence testing are not specific enough to 
give satisfactory results in incidence estimation; neither can they be used for clinical 
purposes to identify recently infected individuals. It is thus important to understand 
the properties of the BED assay and how other HIV disease markers such as viral 
load, CD4 cell count, and initiation of ART relate to the performance of this assay.  
Although the BED assay was validated using serial samples of seroconvertors with 
known timing of infection, this validation process misses important information on 
long term infected patients. Ignoring these long term infected patients affects the 
specificity of the BED assay, giving imprecise estimates of HIV incidence when 
applied in cross-sectional samples.  
 
The 3A11-LS had short-comings similar to those of the  BED assay;  4% of 
chronically HIV infected patients remained below the threshold years after 
seroconversion , and 8.7% of AIDS patients were classified as recently infected [30]. 
Both the 3A11-LS and BED assays falsely classified 2% to 5% of AIDS patients as 
recent infections [15]. The rate of false recent infection was higher among patients 
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about to start ART, and this rate was even higher when patients with very low CD4 
cell counts where considered [98].  
 
AIDS patients were more likely to be misclassified (4.38%), than chronic, (1.69%) 
patients known to have been infected for more than a year [35]. Immune function 
declines during the AIDS stage of HIV disease, and high viral antigens can combine 
with antibodies effectively reducing viral antigens available for titer, proportion  or 
affinity, thus resulting in AIDS patients being falsely classified as new infections [33].  
In our study on patients about to start ART, 11.2 % of patients who were about to start 
ARV treatment had BED ODn values below 0.8, and this percentage was even higher 
(20.2%) among patients with very low CD4 counts. Although there was no data to 
differentiate patients who started treatment based on CD4 count or AIDS defining 
conditions, it is possible that those with very low CD4 counts were also likely to have 
other co-morbidities. In the ZVITAMBO study, among post-partum women, disease 
state seemed not to be related to being falsely classified as recent; for women with 
CD4 counts < 200, 200-399, 400 – 599, 600 – 799 or 800 or more, the false positive 
percentage was 4.5, 3.0, 6.1, 6.5, and 5.4 % respectively.  In the same study, women 
known to have been infected for at least 12 months who subsequently died between 
12 and 24 months after recruitment had a false positive percent of 5.4%,  which was 
not very different from 5.2 % among women last seen alive between 12 and 24 after 
recruitment [52]. In another study AIDS patients had a similar rate of false positivity 
to that observed among long term infected people without AIDS [35].   
 
In the ZVITAMBO study mother and/or child were excluded from the study if either 
had a life threatening condition or if the baby was of very low birth weight (< 1500 
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g). HIV infection is possibly associated with increased risk of abortions, still births, 
early neonatal deaths and low birth weight [99]. This means exclusion from the study 
was likely to be associated with advanced maternal disease, but some excluded 
participants could have been due to poor child outcomes associated with maternal 
seroconversion during pregnancy. The prognosis of babies early on in life for these 
infected in utero has been reported to be worse than those infected intra-partum and 
those infected post-partum through breastfeeding [100]. The exclusion criteria could 
have resulted in biased estimates of in-utero infection associated with maternal 
seroconversion during pregnancy, i.e. in utero transmission rates could in fact have 
been under-estimated. The BED assay could be used on stored samples to investigate 
whether seroconversion during pregnancy is associated with adverse pregnancy 
outcomes.  
 
Although the transmission rate from acutely infected individuals is much higher than 
that from chronically infected individuals, in an advanced epidemic there are far more 
chronically infected persons than acutely infected persons, and thus the chronically 
infected persons account for a larger percentage of incident infections  [101-102].  
Pinkerton et al. estimated that about 8.6% of around 32 000 sexually transmitted HIV 
infections acquired each year in the US were due to acute-phase transmission [102]. 
Xiridou et al. estimated that 11% of incident HIV infections among gay men in 
Amsterdam could be attributed to acute-phase infection [103].   
 
5.1 Properties of the BED assay 
The shape of the relationship between the probability of being recently infected and 
the BED assay was investigated in a sample of new and long term infected post-
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partum women. The influence of viral load, haemoglobin and MUAC on this 
relationship was investigated. 
 
Viral load has been reported as the strongest predictor of the risk of all forms of HIV 
transmission [62-63]. The natural history of HIV serological markers show that these 
markers are likely to be correlated. In fractional polynomial regression models 
although BED, viral load and haemoglobin were all significant predictors of the 
probability of being recently infected, viral load and haemoglobin seemed to capture 
other aspects of HIV disease from that captured by the BED assay. The proportions of 
correctly classified individuals were similar in a univariable model containing BED 
and a multivariable model adjusted for viral load and haemoglobin. In this study, 
using the restricted analysis population in which the recent and long-term infected 
were well defined, resulted in a good separation between those recently infected and 
those known to have been infected for at least a year, which is similar to results found 
from validation studies using serial validation panels with known timing of infection.  
Addition of viral load and haemoglobin, however, did not improve the classification 
of BED, yielding at most a 1% absolute change in agreement.  In another study all 
individuals with mean uncertainty of 10 days between last negative test and first-
positive test were correctly classified,  but this declined to 73% when the mean 
uncertainty increased to 140 days [35].  In our study the restricted analysis population 
had a higher likelihood of being correctly classified than the full analysis population 
where the timing of infection was less certain. In McNicholl et al.’s study, BED 
derived cross sectional HIV incidence estimates were similar to longitudinal incidence 
estimates when the assay was applied to people with known timing of being recently 
infected. In the same study, when the analysis included long-term infections,  the 
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incidence estimates by BED were higher [104]. This has been cited as the main 
weakness of the BED assay.  
 
5.2 Variability in HIV serological markers 
The proportions of long term HIV infected individuals who present with low BED 
readings seems to vary widely, depending on subtype, population prevalence, and 
time [89]. The BED assay, similar to other HIV serological markers such as the LS 
assay, CD4 cell count and viral load is variable within and between infected patients.  
 
If populations differ in concentrations of IgG, then the BED assay would not be 
expected to perform the same in these different populations. For example, if normal 
IgG concentration ranges are lower in Caucasian than African populations, 
seroconversion durations may be shorter in Caucasian populations, assuming similar 
HIV antibodies synthesis kinetics [33]. Total IgG levels are known to be significantly 
elevated among Africans, and malnutrition, which is a common occurrence in Africa, 
has been linked to immunologic dysfunction [105-106]. Conditions or co-infections 
that elevate total IgG (hypergammaglobulinemia) may result in long term infected 
individuals falsely classifying as new infections, a situation that may be true in Sub-
Saharan Africa. The onset of opportunistic infections due to advanced HIV disease 
and immune reconstitution after the commencement of antiretroviral therapy seem to 
result in a decrease of HIV specific IgG [107-108]. The effect of other co-infections 
such as TB, pneumonia and a host of other opportunistic infections commonly 
associated with HIV were not evaluated in this study.  Further research is needed on 
the relationship between BED and other specific opportunistic infections.    
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There have been observed differences in immune response to HIV between African 
and European populations especially regarding CD4 cell counts [109]. Some studies 
have reported that individuals with low CD4 count/high viral loads are much more 
likely to be misclassified on the BED assay than infected individuals with high CD4 
count/low viral loads [98]. CD4 cell count levels vary greatly both within and among 
populations for reasons that are not yet fully understood. It has been noted that 
individuals’ CD4 counts may vary by as much as 200/µl in readings taken a few 
weeks apart [110]. There were no observed differences in CD4 cell levels at time of 
seroconversion between individuals whose progression to AIDs was normal, rapid or 
slow within a 2 to 6 year follow-up multi-centre study [111-112].   
 
BED cut-off levels used in classifying HIV infected patients were first determined 
empirically and later refined and confirmed using statistical models [35]. For a BED 
cut-off of 1.0 corresponding to a mean window period of 158 days, the BED assay 
had sensitivity and specificity of 82% and 89%, respectively, and an accuracy rate in 
incidence calculation of 93% in combined subtypes B and E [35]. Subtype B in the 
same study had a slightly longer window (186 days) period than E (152 days). Karita 
et al. reported unusually high proportions of persistently high false recent rates (26.7 
% to 57.1%) on the BED assay among HIV patients infected for at least a year.  
According to the same study, the proportions seemed to vary with subtype; 30.4 % in 
subtype-C and 57.1 % in subtype A1.The authors reported that plasma viral load was 
significantly lower over a year of follow-up among volunteers who tested false 
positive as being recently infected compared with those whose BED values correctly 
indicated them as being long-term infected.  Sensitivity (81.2%) in this study was 
similar to the Parekh et al. study, but specificity was much lower (67.8%).   The 
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authors reported that the optimal cut-off on the ROC curve that would give acceptable 
sensitivity and specificity was 0.5, corresponding to a window period of 80 days [34].   
 
Although Karita et al.’s estimates are based on relatively small sample sizes; this 
highlights the issues of wide variability in BED performance across subtypes and 
regions. Hallett et al. did a systematic review of the BED assay and reported that the 
BED assay performs differently across regions, time and subtype [89]. The 
ZVITAMBO study had an estimated mean window of 187 days using a cut-off of 0.8 
among post-natal women carry subtype C [52]. The window period from the VAX004 
study was 133 days compared to 153 days derived from independent seroconversion 
panels [36].  
 
It is still not well understood why the BED assay performs differently in different 
HIV subtypes. A slower HIV IgG synthesis in subtype B infection than E infection or 
a poor recognition of the subtype B peptide by homologous antibodies may explain 
some of these differences [35]. The B peptide used in the assay may perform 
differently because there is heterogeneity even within the same subtype [113]. Disease 
level such as viral load kinetics may explain some of the differences in 
seroconversion duration. For example there was significantly higher HIV viral RNA 
in subtype E compared to subtype B during the first three months of infection [21]. 
The lower viral load in subtype B infection could have resulted in slower kinetics of 
the HIV specific IgG synthesis [35].  Viral kinetics over time as indicated by various 
disease stages such as clinical AIDS where IgG are presumably lower can affect 
performance of the assay thus leading to misclassifications [114-115].  Primary HIV 
infection results in a burst of viral replication that is thought to be controlled by viral 
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specific immune response of the host. Broad HIV specific immune responses may be 
more effective in controlling viral replication than restricted ones [116-118].  Some 
HIV infected individuals are elite viral suppressors, and these individuals’ BED ODn 
profiles progress much more slowly than HIV rapid progressors. The observed ODn 
values of these elite suppressors remain below the cut-off threshold for a long time 
after initial infection [107, 119]. Adjusting for viral load and haemoglobin did not 
improve the performance of the BED assay in our study.  
 
Although the results of antibody assays are reported dichotomously (recent or long 
standing), these categories are defined by quantitative, assay-specific cut-offs. 
Algorithms that make use of the more quantitative nature of these assays might 
provide better predictions of incidence than currently observed. Consideration should 
be made to see if instead of using a single cut-off point, a number of cut-offs with 
varying assigned probabilities of belonging to a class can be more useful.  Assigning 
probability values of being recently infected modelled on BED assay values and other 
correlates of recent infection might be practically more useful than using single cut 
offs. The probability models can investigate a wider range of lymphocyte counts 
besides CD4 cell count. Similar models have been successfully used in vaccine 
efficacy research [120-121].     
 
BED ODn levels are affected by ART; in our study over 50% of the patients who had 
been on ART for over two years tested below the 0.8 cut off of the ODn assay [98]. 
Antiretroviral treatment slows the rate of HIV virus replication, thus altering HIV 
specific response quantitatively (antibody level) or qualitatively (avidity) resulting in 
lower levels of the BED assay [122-123]. It has been reported that complete 
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seroconversion can be achieved much earlier by initiating HAART during acute/early 
HIV infection [124-125]. The BED assay has been successfully used in the USA 
because of readily available medical records for HIV infected patients. This kind of 
data is unlikely to be available in the most affected countries, thus other ways of 
identifying patients on treatment as well as those who have been infected for long 
periods have to be devised. ART provision has increased substantially in some of the 
most affected areas of the world [126], thus data on the number of HIV-infected 
individuals on ART  may progressively become more available. HIV infected 
individuals may be asked to indicate if they are on ART therapy. Since ART affects 
BED ODn levels, the number of HIV-1 infected individuals on ART should be taken 
into account when estimating HIV incidence.  
 
5.3 Risk of MTCT for women who get infected during pregnancy  
It has been shown that the acute phase of infection is associated with an increased risk 
for onward transmission compared to any other times [58, 127]. It is important to 
compare and contrast similarities and differences between different timing of HIV 
transmission. The different mechanisms for MTCT of HIV for example, cannot be 
assumed to be the same, and may be expected to be very different from horizontal 
ways of HIV transmission. It has been shown that without ART, the risk of HIV 
infection is highest during delivery, and lowest during pregnancy [2-3, 128]. But 
within each of these modes of transmission is the risk similar between those with 
acute infection and those with chronic infection?  
 
The probability of transmission from a single coital act during acute infection was 
found to be 43 times than the probability of transmission from a single act during 
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chronic infection [129].  In this study in Rakai, Uganda, as much as 89.1% of all 
infection was estimated to be possibly due to acute infection.  Model estimates 
suggest that the rate of heterosexual HIV-1 transmission per coital act follows a U-
shaped curve, being highest during the post-seroconversion period, lower during 
latency, and increasing with advanced disease [130-132]. This is supported by 
findings that serum HIV viral load, which is high during the post-seroconversion 
period and during advanced disease, is the principal predictor of heterosexual 
transmission [61, 133-134]. It has been shown that high serum viral load is associated 
with an increased probability of heterosexual transmission, thus transiently high 
viremia during acute infection might translate to increased likelihood of onward 
transmission [58, 135-136] . Men with acute HIV infection are biologically more 
infectious because of increased genital shedding of HIV.  During acute infection, HIV 
viral load increases and thereafter decreases in semen, with these changes 
approximately paralleling those that occur in blood. Viral dynamics in semen suggest 
that on average individuals are hyper-infectious at the onset of the acute retroviral 
syndrome period  and continuing for ~ 6 weeks thereafter [137].  Men in sub-Saharan 
Africa with clade C have been shown to have 3-4 fold higher viral load compared to 
clade B and E predominant in Europe, even without STD co-infections [109, 137].   
 
It is important to understand the serological kinetics associated with different modes 
of HIV infection.  It cannot just be assumed that transmission dynamics for mother-to-
child are similar to heterosexual transmission. For example, although serum viral 
loads are usually used as a measure of infectiousness, the key driver of sexual 
transmission is genital fluids (and not blood), thus making it difficult to model HIV 
transmission during acute infection on the basis of blood alone. This is partly 
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explained by the fact that acute HIV infection represents a period of initial 
establishment of anatomic HIV-1 reservoirs; therefore the viral dynamics in blood, 
which have been well described for acute HIV infection [138-141] cannot be assumed 
to apply to the genital tract.  If viral load were to increase more rapidly in genital 
fluids than in the systemic compartment, for instance, the probability of transmission 
during acute HIV-1 infection would be greater than that predicted on the basis of 
concurrent blood HIV-1 load. If on the other hand semen viral load were to increase 
slowly, relative to blood viral load, it is possible that no peak in probability of 
transmission would occur at all, despite elevated blood VL during acute infection. 
These same arguments can be used when assessing HIV risk associated with MTCT 
of HIV. In a study of post-partum women who were breastfeeding, women who 
seroconverted had median plasma viral load of log10 5 (IQR 3.5 – 5.8) at time of 
infection, and log10 4.1 (IQR 3.7 – 4.7) one year after the last negative test. Breast 
milk supernatant viral load for the same group of women, was lower ; log10 2.2 (IQR 
1.9 – 3.1) and log10 1.4 (IQR 1.4 – 2.1) for the same time points respectively [58].  
 
We used BED and CD4 cell count to estimate the risk associated with low BED 
reading typical of recent infections. The risk of in utero infection was highest among 
women with low BED values (ODn < 0.8) and low (< 200) to moderate (200 - 349) 
CD4 cell counts, 3.4 times and 2.6 times higher compared to women with  high BED 
(≥ 0.8) and high CD4 cell counts  (≥ 350) [142]. Yet the risk patterns in intra-partum 
infections were somewhat different to in utero infections; women with low BED and 
low CD4 counts had twice the risk of transmitting HIV to their babies intra partum 
compared to those with high BED (≥ 0.8) and high CD4 cell counts  (≥ 350). The risk 
group with the highest HIV transmitting probability probably consists mainly of 
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women who seroconverted during pregnancy. Although this kind of classification has 
its own limitations, it was clear that various groupings of BED and CD4 cell counts 
quantified different risk levels posed by pregnancy and delivery. This suggests that 
HIV negative pregnant women must be tested more than once during antenatal visits.  
 
In a breast feeding study, women who seroconverted in the post partum period were 
more likely to transmit HIV to their breastfed babies compared to women who were 
already HIV infected at the time of delivery. Although in high prevalence areas like 
Zimbabwe where post-natal incidence rates were estimated to be 3.4 per 100 person 
years[52], post-natal seroconversion has been estimated to contribute as much as  
20% of all breastfeeding transmission [58].  
 
5.4 Use of the BED and other serological assays 
Serological assays such as the BED or the 3A11-Ls assay can be used at the 
population level for estimating HIV-1 incidence, and for identifying subjects with 
early infection for therapeutic trials and pathogenesis studies, and at public health 
level for focusing and evaluating HIV prevention efforts [30]. It should however been 
noted that these assays have poor specificity.  
 
Antibodies to HIV develop during primary HIV infection, thus may not be detected 
by HIV antibody tests.  If effective identification and thus appropriate intervention 
programs targeted specifically to new infection are to be made, assays that identify 
recently infected patients with high levels of certainty are needed.  
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Montaner et al. proposed what they termed “test and treat”, where universal testing of 
the whole population takes place and everyone found to be HIV infected immediately 
commences on ART [143]. The argument used is similar to HIV prophylaxis used for 
PMTCT programs. Treated mothers are less infectious, thus MTCT rates has been 
reduced to very low levels. Mathematical models have suggested that the test and treat 
strategy could result in new infections coming down substantially [144-146]. Strong 
arguments for this radical approach are that current HIV preventive methods have 
shown little effectiveness, effective preventive vaccines seem a long way off and that 
current treatment methods cannot eradicate HIV infection [147-151]. Although the 
test and treat algorithm is an attractive proposal, treating every HIV infected person is 
unlikely to be feasible and in a resource constrained setting it would be ethically 
challenging to treat those acutely infected in preference to treating patients with 
advanced HIV disease who qualify for treatment under current guidelines. Algorithms 
that incorporate assays such as the BED assay may be used to develop modified test 
and treat protocols that are more practical and feasible. These assays can be used to 
identify high risk groups thus targeted interventions implemented. These should 
include identification of possible new infections for partner notifications as well as 
identifying sexual networks, thus reducing onward transmission [30].  
 
Viral load is known to be elevated during the acute phase of infection and towards 
end stage disease (AIDS stage).  This means people at extreme ends of the disease can 
present with similar viral loads, thus there is need to use other disease markers such as 
BED, CD4 and haemoglobin to define different risk algorithms that differentiate risk 
profiles in order to reduce the risk of onward transmission. 
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It has been proposed that despite the BED assay’s imperfections, differences in 
estimated incidence in the same population over time or between subgroups of the 
same population are probably valid because errors, biases, and variances in the assay 
are expected to be stable over time [95, 152-158]. This means these anti-body 
incidence assays may be used to examine trends of HIV-1 incidence over time in the 
same population and to assess the effectiveness of pre and post interventions and to 
compare incidence between two or more groups from the same population or to assess 
trends, a common objective in public health.  Well known established epidemiological 
facts should guide the use and interpretation of results obtained in incidence data 
using these assays.  
 
5.5 Limitations of cross-sectional serological assays  
Questions have been raised as to how comparable cross-sectional HIV incidence 
assay based estimates are to longitudinal estimates. BED measures historical exposure 
that may not span the same time period as cohort studies.  The rate of 
misclassification on the BED assay may depend on time if individuals with fully 
developed immune responses live longer than other HIV patients [107, 119].  This 
means that the assumption of constant false positive rate may only be true in relatively 
short periods.  McDougal et al. demonstrated increased incidence estimates from 
2.94% to 5.45% when prevalence changed from 3% to 20% with a fixed false recent 
percentage of 5% [36].This means that changes in or differences in prevalence even 
within the same group might affect incidence estimates substantially.  In generalised 
epidemics the proportion of long term infected may be quite high. Sakarovitch et al. 
demonstrated that different assays would overestimate HIV incidence by different 
amounts  when true incidence is very low relative to prevalence. For example, 
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assuming an incidence of 1% and prevalence of 30%, the IDE-V3 assay gave HIV 
incidence estimates that were 3 times higher, Vironostika 17 times higher, BED 20 
times higher and the avidity test gave HIV incidence estimates that were 36 times 
higher than the true incidence value. In this study, the observed bias in estimated 
incidence increased when the simulated incidence rate decreased, which raises the 
question as to whether these tests can be used to reliably monitor incidence trends 
over time [159].    In a study using data from Abidjan where prevalence was 10% 
[160] and incidence was 1% [161], four HIV incidence assays (Vironostike, Avidity, 
IDE-V3 and BED) would have failed to identify a decrease of 50% in incidence; the 
BED would have given an incidence decrease from 6.2% to 5.1% (a 5% relative 
decrease), Vironostika 5.5% to 5.1% (7% relative decrease), IDE-V3 1.2 % to 1.0% 
(17 % relative decrease) and avidity 11.2 to 11% (2% decrease) [159].  
 
Incidence estimates derived from cross sectional samples measure the number of 
recent infections per period, e.g. 186 days for subtype C or the appropriate window 
depending on subtype. Extrapolation of this value to a longer period for example 
when calculating an annualized estimate assumes constant rate of infection during this 
one year period. A non constant rate over the estimation period might result in biased 
results [104]. The magnitude of bias associated with false-recent positives using the 
BED assay can be substantial, increasing with prevalence as noted in a number of 
studies [35-36, 52, 162-164].  
 
Individuals who are elite or viremic controllers with low or undetectable viral loads 
may remain in the window period of the BED assay until AIDS or death, thus creating 
what Brookmeyer et al. termed an assay shadow [165]. According to the author long 
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shadows (2 years or longer) can create discrepancies between cohort and biomarker 
incidence estimates especially if incidence changes sharply over time. This means for 
instance longitudinally obtained estimates may be biased when used to validate assay 
based estimates because these two methods are measuring HIV incidence at different 
time points. 
 
A number of ways to improve the performance of the BED assay or similar assays 
have been proposed. A single specimen can be tested for levels of antibodies to two or 
more different proteins or peptides representing early and late infection [33]. Two or 
more different methods such as proportion or titer of HIV-IgG and antibody avidity 
can be combined into a single assay [33].  Because of wide variation in immune 
response, single stand alone serological approaches for measuring HIV infections are 
unlikely to better the 85% observed sensitivity and specificity of the BED assay [35]. 
Issues such as individuals with late stage disease or opportunistic infections, or those 
receiving therapy need to be addressed before applying these tests to reduce the bias 
in the estimates of incidence.  To account for these, certain specimens could be 
excluded on clinical grounds, secondary confirmatory assays may be used or 
mathematical analytical adjustments may be used [36]. Participants who self report or 
otherwise are known to be long term HIV-1 positive [166-167] patients with AIDS 
[30, 168], or patients receiving antiretroviral therapy [65] are unlikely to be recently 
infected and likely to register as recent by the assay, thus should be accounted for 
when estimating HIV incidence. More stringent testing algorithms can be used, for 
example requiring a confirmatory test with a second test for recent infection or asking 
patients if they are on ART if they present with low BED ODn readings.   
Mathematical adjustments have been proposed, and they rely on getting an accurate 
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estimate of false recent rates [35, 52, 164]. A number of studies have reported the 
percentage of HIV patients who present with low BED ODn levels despite being 
infected for periods longer than the BED window period [34, 52, 169-170] and this 
varies from 1.7% in SA [169] to as high as 27% in Rwanda and Zambia [34]. This 
brings into question the generalizability of applying mathematical methods in 
incidence calculations to account for the rate of false positivity. The use of false 
positive proportions that are not locally derived have resulted in unrealistically high 
estimates of incidence in Cote d’Ivoire[170], South Africa [55, 169] and Uganda 
[171]. The recency period (window) may differ by subtype [172] requiring selection 
of appropriate window periods for populations in the same area such as Thailand, 
where more than one subtype predominates [104].  This limits the wide use of the 
BED, because genotyping may be required, thus making the use of these assays even 
more complex. One promising strategy is based on algorithms involving multiple 
assays such as CD4, BED, avidity assays, p24 antigen, HIV RNA screening and 
presence of antiretroviral drugs [107]. Some of the proposed strategies are however 
likely to make these assay expensive and technically complex to implement, a huge 
drawback for the most affected regions of the world. Janssen et al. propose using CD4 
cell count to supplement the assay classification for clinical care of patients [30].  
A number of population level epidemiological adjustment methods have been 
proposed, and these correct the naïve incidence estimates by correcting assay 
imperfections: window period, short and long term false recent rate and sensitivity of 
the test [36, 52, 173] . 
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5.6 Key Summary Findings 
i. It was shown that ART reduces HIV specific IgG levels; over half of patients 
presented with BED levels typical of recently infected patients. Most patients 
put on ART are likely to be advanced stage patients, thus they should be 
accounted for when estimating HIV incidence using the BED assay. 
ii. The proportion of long term infected patients testing as recently infected can 
be substantial, as much as 11% of HIV advanced stage patients had low BED 
ODn levels. This rate seems to be higher than other rates obtained in a general 
HIV infected population. Patients with very low CD4 count were more likely 
to present with low BED values.  
iii. The BED assay, in combination with other serological markers can be used as 
a prognostic tool to assess historical risk of in-utero HIV infection in stored 
sera. Different combinations of BED and CD4 cell count presented with 
different risk measures of in utero and intra-partum infection 
iv. HIV negative pregnant women who normally have a single HIV test earlier on 
during the antenatal period may benefit from retesting. The women carry a 
disproportionate risk of transmitting to the unborn child if they get infected, 
thus may not benefit from PMTCT programs if they are not tested again.  
v. The BED assay and other serological markers such as viral load and 
haemoglobin seem to measure different aspects of the HIV disease. Addition 
of viral load and haemoglobin seem not to have changed the predictive ability 
of the BED assay for recent infections in a cross-sectional sample.  
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5.7 Future work 
Although the BED assay is not specific enough to correctly identify new HIV 
infections, it has great potential in other HIV programmes. Measuring viral load is 
relatively expensive and it requires specialised equipment and expertise. Algorithms 
combining CD4 count, which is routinely collected and BED ODn which is 
technically simpler to perform might be good proxies for viral load in assessing HIV 
risk.  
 
Novel proposals on ‘test and treat’ have been made. These proposals though 
theoretically very attractive are unlikely to be implementable in the near future 
because of costs and commitment from funders of HIV programs. Algorithms 
profiling different risks can be developed and these might be useful in the 
management of the HIV disease.  
 
The BED assay is based on changing levels of HIV specific IgG as a function of total 
IgG. The effect of other co-infections on BED readings is not clear, thus future work 
should be carried out to investigate how co-infections such as TB, malaria and 
pneumonia affect BED levels. Anti-retroviral treatment is known to alter and reduce 
BED ODn levels. The effect of other drugs such as anti-TB drugs should also be 
investigated to see if they have a similar effect on BED readings.  
 
Questions have been raised as to whether the BED assay can be used to evaluate HIV 
prevention interventions, where the aim is not to get precise estimates of incidence but 
to capture changes in incidence over time. Future work should be done to assess if the 
BED assay can be used to measure the impact of interventions. These studies should 
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use independent confirmatory methods in order to assess possible biases associated 
with using the BED assay. The studies have to cover wide HIV incidence ranges in 
order to measure the sensitivity of the assay.  
 
 
The role of other health markers such as haemoglobin on the likelihood of testing 
recent on the BED assay is not yet fully understood. In our study, haemoglobin was 
only measured at baseline, and there was limited CD4 cell count data on 
seroconvertors, thus limiting our inference on the full effects of these two markers. 
Further research on the relationship between these various markers might shed more 
light on why some HIV infected individuals present with low BED readings a long 
time after being infected.  
 
Current proposed HIV incidence formulae adjust for the non specificity of the BED 
assay using the window period of the assay [36, 52, 173-174]. The assay window 
period is derived from BED ODn panel data. Further research using different 
weighting systems based on the window period and/or BED ODn levels might give 
more precise estimates of incidence.    
 
5.8 Conclusion  
Major gains have been made in reducing the number of babies born with HIV by 
using HIV prophylaxis during pregnancy and after delivery. These reductions are 
mostly observed on the number of intra-partum and breastfeeding associated 
transmission where rates have gone down to single digit figures in most areas. HIV 
transmission to the unborn child is thought to occur late during pregnancy. Pregnancy 
associated transmissions to the unborn child will increasingly become the focus of 
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PMTCT research. Current HIV prophylactic guidelines for pregnant women say 
treatment should commence as soon as a women test positive or at least at 14 weeks 
gestation [175]. Women who acquire HIV during pregnancy may pose a higher risk of 
infecting their unborn children than long term infected women. Identifying this high 
risk group may be missed because of a single HIV test. Pregnant women should thus 
be encouraged to seek antenatal care early in order to achieve optimal benefits of 
PMTCT programmes. Repeat HIV tests for pregnant women in high HIV prevalent 
areas as well as in high risk groups may identify recently infected women.  Although 
incidence rates may be relatively small, the absolute number of infected babies may 
be substantial especially in settings with high HIV prevalence, thus prevention 
strategies to avoid new infections should continue.   
 
There are benefits in identifying recently infected individuals because these 
individuals carry a disproportionately high risk of onward transmission of HIV. More 
conservative criteria such as lowering the cut-off of the BED assay may be used to 
increase the likelihood of picking up truly recently infected individuals as well as 
such other high risk individuals [35]. Besides antenatal and maternal patients, all such 
patients with elevated risk of onward HIV transmission would benefit from ARV 
treatment.  An easy and fast way of identifying newly HIV-1 infected individuals can 
result in prescribing ART early, thus reducing the chance of establishment of 
reservoirs of tissue of the HIV virus [19-20, 176]. Early treatment coupled with 
appropriate counselling and partner notification might help in reducing secondary 
transmission from newly infected individuals to their sexual partners [38, 156, 177]. 
The potential clinical benefits of antiretroviral treatment for individual patients who 
are diagnosed during antibody-negative acute infection further emphasize the need for 
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improved and early identification of cases of HIV-1 infection [178]. Treatment 
consideration for recent sex contacts should include prospective screening for acute 
and chronic HIV infection and appropriate screening for other sexually transmitted 
pathogens.  It is conceivable that antiretroviral treatment in early infection may reduce 
the risk of onward transmission, and treated patients may benefit from better immune 
control and lower set points of viremia [136, 179].  With less than 100% ART 
coverage for people in need of treatment, there are serious ethical issues associated 
with who should be considered for treatment, recently infected person to reduce the 
risk of onward transmission or sick people who may die if treatment is withheld. It is 
however important to actively seek out recently infected persons and to propose 
counselling to reduce high risk behaviour during this critical period [136, 153].  
 
Cross-sectional assays such as the BED are advantageous because they can measure 
historical risks such as risk of MTCT during pregnancy.  The risks associated with 
different pregnancy periods (trimesters) can thus be compared.   
 
Symptomatic seroconversion illnesses are nonspecific such that they are usually 
misdiagnosed and as such a large number of HIV infected patients do not seek 
medical care [180-182]. This means clinical assessment of primary HIV infection is 
limited, emphasizing the urgent need for cross sectional assays such as the BED assay 
that can be used to assess risk of recent infection, enabling targeted versions of test 
and treat to be implemented.    
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